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Zusammenfassung
Apoptotische Zellen induzieren einen tolerogenen Pha¨notyp in dentritischen Zellen (DC)
und tragen damit zur Entwicklung und Erhaltung von peripherer Toleranz bei. Unsere
Gruppe erforscht den Einfluss von apoptotischen Zellen auf DC und entdeckte, dass die
evolutiona¨r konservierte Annexin-Kerndoma¨ne (Anx) auf der Oberfla¨che von apoptot-
ischen Zellen pra¨sent ist und als immunsuppressiver Mediator der Aktivierung von Toll-
like Rezeptor (TLR) signalling entgegenwirkt.
Diese Studie analysierte, ob die tolerogenen Eigenschaften von Anx daru¨ber hinaus Antigen-
spezifische Immunreaktionen gegen das Modellantigen Ovalbumin (Ova) regulieren kann.
Sowohl die Vorbehandlung von bone marrow-derived dendritic cells (BMDC) mit lo¨slichem
Anx als auch die Behandlung von BMDCmit Beads, an die Anx und Ova gebunden wurde,
fu¨hrte zu einer reduzierten Ova-spezifischen T-Zell-Antwort. Die Ova-spezifischen OT-II
T-Zellen zeigten vermindertes Wachstum und verminderte Zytokinsekretion und somit
einen Anergie-a¨hnlichen Pha¨notyp nach der Ko-Kultivierung mit behandelten BMDC.
Die anti-inflammatorische Aktivita¨t von Anx wird u¨ber die DC vermittelt. Allerdings
sind die dafu¨r verantwortlichen Mechanismen noch unklar. Im Gegensatz zu apoptot-
ischen Zellen, induzierte Anx keinen tolerogenen Pha¨notyp in BMDC. Es konnte sogar
gezeigt werden, dass die zuvor in der Literatur beschriebene Zytokinsuppression keinen
Einfluss auf die Inhibition von T-Zellen hat. In dieser Studie konnte jedoch eine erho¨hte
Produktion von reaktive Sauerstoffspezies (ROS) als ein neuer Anx-induzierte Effektor
in BMDC identifiziert werden. Diese ROS ko¨nnten sowohl die DC selbst als auch die
DC-T-Zell-Interaktion beeinflussen.
Obwohl die Mechanismen hinter der Anx-vermittelten Suppression nicht aufgekla¨rt wer-
den konnten, demonstriert diese Studie, dass Anx genutzt werden kann, um ein Partikel-
basiertes System mit Antigen-spezifischen, immunsuppressiven Eigenschaften zu entwick-
eln. Anx-Partikel dieser Art ko¨nnten als neue Therapieoption in Autoimmunerkrankun-
gen genutzt werden und ko¨nnten somit eine Alternative zu der aktuellen Behandlung mit
allgemeinen Immunsuppresiva darstellen.
IX

Abstract
Apoptotic cells mediate the development of tolerogenic dendritic cells (DC) and thus facil-
itate the induction and maintenance of peripheral tolerance. Our group investigated the
influence of apoptotic cells on DC and identified the cell surface exposure of the evolution-
ary conserved annexin core domain (Anx) as a specific signal which antagonises Toll-like
receptor (TLR) signalling.
This study examined whether the tolerogenic capacity of Anx can be exploited to down-
regulate antigen-specific immune responses to the model antigen ovalbumin (Ova). The
treatment of bone marrow-derived dendritic cells (BMDC) with soluble Anx prior to Ova
administration or the treatment with beads harbouring Anx as well as Ova attenuated the
response of Ova-specific OT-II T cells. The co-culture of treated DC and T cells resulted
in an anergy-like phenotype characterised by reduced proliferation and cytokine secretion.
The anti-inflammatory effects of Anx are mediated through DC by yet unknown mech-
anisms. Anx did not lead to the tolerogenic DC phenotype described to be induced
by apoptotic cells and also the previously reported suppression of anti-inflammatory cy-
tokines by Anx was dispensable for the effect on T cells. However, this study revealed
enhanced production od reactive oxygen species (ROS) in BMDC in response to Anx
which might affect the DC/T cell interactions.
Although the underlying mechanisms remain to be elucidated, this study demonstrates
that Anx can be used as a tool to generate a particle-based antigen delivery system that
promotes antigen-specific immunosuppression. Such Anx-particles may be a new thera-
peutic approach for the treatment of autoimmune disease.
XI
1 Introduction
1 Introduction
1.1 The immune system
1.1.1 Innate immunity
The immune system is vital to protect the organism from invading pathogens, toxins and
other dangers. The innate immune response is evolutionary well conserved and can be
found, at least partially, in all living organisms. It represents a first line of defence and can
be sufficient to eliminate an infection. Innate immunity relies on the recognition of com-
mon pathogen structures called pathogen-associated molecular patterns (PAMP) which
in turn are sensed by a defined set of pattern recognition receptors (PRR). Granulocytes,
NK cells, macrophages (Mφ) and dendritic cells (DC) are cells of the innate immune sys-
tem and have three major tasks: phagocytose pathogens and infected cells, lyse them and
activate the adaptive immune system. 1
Mφ, as their name implies (greek: big eaters), are the main phagocytes of the immune
system. In addition to engulfing pathogens and infected cells they are also responsible for
clearance of apoptotic cells and their debris. They are also capable of shaping immune re-
sponses by the secretion of inflammatory mediators including cytokines. 2 However, their
direct interaction with cells of the adaptive immune system is rather limited 3.
The main inducers of adaptive immune responses are DC 2. They continuously sample
their environment via phagocytosis, receptor-mediated endocytosis and macropinocytosis
to present antigens to the adaptive immune system. DC are the most efficient antigen
presenting cells (APC) since they are capable of presenting even picomolar concentra-
tions of antigen 3,4. Antigens must be presented in a specific form, hence the antigens are
processed and loaded onto major histocompatibility complexes (MHC). Depending on the
mechanism of uptake and compartment localisation, the antigen is presented on MHC class
I or II and thus presented to CD8+ or CD4+ Tcells, respectively. Exogenous antigens but
also cytosolic proteins that are processed in endolysosomes can be loaded onto MHC II.
Endogenous proteins are rather processed by the proteasome in the cytosol and then
transported into the endoplasmatic reticulum (ER) where they are loaded onto MHC I
molecules. Under certain conditions, exogenous proteins can escape into the cytosol where
they are subject to proteasomal degradation and hence get loaded onto MHC I. Present-
ation of exogenous antigens within MHC I is also called cross-presentation. 5,6
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1.1.2 Adaptive immunity
The adaptive immune system comprises B and T lymphocytes and, in contrast to the
innate immune system, elicits antigen specific immune responses. A lymphocyte can only
respond to a single antigen defined by the specificity of the T cell and B cell receptor
(TCR and BCR, respectively) which are generated via somatic recombination. 7,8
Tcells can only be activated upon interaction with APC and the resulting T cell response
is shaped by three signals. The first signal is the binding of the TCR to antigen-loaded
MHC on the DC which assures antigen specificity. CD8+Tcells can only recognise MHC I
while CD4+Tcells recognise MHC II. The second signal is co-stimulation, referring to an
interaction of CD28 on the T cell with B7 molecules on the APC. The third signal are cy-
tokines which are necessary for differentiation of naive T cells into effector T cells. 7,9 Signal
2 and 3 are decisive for the type of T cell response, which can be immunogenic or tolero-
genic. Immunogenic responses on the one side can be triggered by engagement of CD28
with CD80 or CD86 in conjugation with pro-inflammatory cytokines like interleukin-6
(IL-6) or IL-12 and is also supported by CD40/CD40L interaction. The latter acts as a
positive feedback loop for the DC 9,10. On the other side, a tolerogenic outcome is favoured
by interactions of inhibitory co-receptors and supported by anti-inflammatory cytokines
like IL-10 or transforming growth factor β (TGF-β). 9,11
Co-inhibition is essential to regulate and limit T cell responses (fig. 1). The most critical
co-receptor on the T cell surface in this respect seems to be cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) since the loss of only this receptor leads to severe and
fatal autoimmune disease 12,13. Furthermore, the blockade of CTLA-4 is associated with
severe autoimmune-like toxicities 14,15. CTLA-4 is expressed upon T cell activation and,
as a homologue of CD28, it also binds CD80 and CD86, but with an opposing, inhibitory
outcome. 16 CTLA-4 has a higher binding affinity to CD80/CD86 than CD28 and can
limit the interaction of CD80/CD86 with CD28. 17 Besides being a competitor for CD28,
CTLA-4 interferes with TCR signalling and hence acts as an intrinsic T cell regulator. 16
The second most important co-inhibitor seems to be programmed cell death protein 1
(PD-1). Albeit, deficiency or blockade of PD-1 provokes autoimmunity, the etiology and
symptoms are milder than those observed in the context of CTLA-4. 15,18,19 Similar to
CTLA-4, PD-1 is expressed upon T cell activation and binds to PD-L1 and PD-L2 on
the APC surface. PD-L1 is constitutively expressed whereas PD-L2 expression depends
on the maturation status of the APC. 20 Upon ligation with one of its ligands, PD-1
antagonises T cell activation by initiating dephosphorylation of TCR and CD28 signalling
molecules. 21
PD-1 seems to be co-expressed and to have synergistic functions with other co-receptors,
2
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subtypes of T helper (TH) cells. TH1 responses are characterised by IL-2 and IFN-γ se-
cretion which can counteract e.g. intracellular pathogens and tumours. TH2 cells secrete
IL-4, IL-5 and IL-13 to support B cell responses against exogenous pathogens or allergens.
And TH17 cells, which mainly produce IL-17, are implicated in maintaining mucosal bar-
riers. 7 Tolerogenic T cell differentiation will be addressed in 1.2.2.3.
1.2 Immunotolerance
Somatic recombination generates a diverse TCR repertoire which is essential to ensure
a response against a huge variety of pathogenic antigens. However, this random gene
rearrangement also leads to TCRs recognising structures of the own tissue called self-
antigens. Self-reactive T cells can cause autoimmune disease and hence must be eliminated
or tightly controlled.
1.2.1 Central tolerance
Central tolerance is a two step process that controls T cell reactivity during T cell develop-
ment in the thymus. First, thymocytes, which are precursors of T cells, are positively selec-
ted for a functional TCR, which can recognise MHC molecules. Upon TCR rearrangement
and upregulation of CD4 and CD8 co-receptors, the thymocytes are tested for binding to
peptide-MHC complex (pMHC) in the thymic cortex. Thymocytes without a functional
TCR die while thymocytes with baseline binding to pMHC migrate to the thymic medulla
where they encounter medullary thymic epithelial cells (mTEC) and thymic DC present-
ing self-antigens. Recognitions of self-antigens by the TCR leads to negative selection
and hence elimination of thymocytes with strong self-reactivity. Thymocytes with a TCR
that binds weakly to self-antigens can survive negative selection and are programmed to
become regulatory T cells (Treg) by the upregulation of the transcription factor Foxp3. 36
1.2.2 Peripheral tolerance
Although many self-reactive T cell clones undergo apoptosis during central tolerance, this
system is imperfect and self-reactive T cells escape into the periphery where they must
be controlled by peripheral tolerance mechanisms.
1.2.2.1 Tolerogenic dendritic cells
DC are in the centre of immunity and thus control pro- and anti-inflammatory T cell re-
sponses. Deletion of DC in mice results in severe autoimmunity emphasising the role of
DC in maintaining tolerance 37. However, DC can also contribute to autoimmunity. Dys-
regulated or aberrant DC activation can break tolerance and drive autoimmunity which
is illustrated in various mouse models where transfer of such DC promote autoimmune
4
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disease in healthy recipients 38–40. Moreover, human patients show high numbers of DC
in autoimmune lesions 41.
DC with the capacity to maintain tolerance are commonly referred to as tolerogenic DC
(tolDC) but whether location, subtype or maturation state characterise tolDC is still a
matter of debate. The subtype of CD8α+DC, for example, is often mentioned in this
context despite the fact that this subset is the only subset inducing tolerance 42,43.
The location or environment can have great influence on the function of DC. Organs
like the spleen, where CD8α+DC are mainly located, or the liver are described to fa-
vour tolerance e.g. by the presence of anti-inflammatory factors such as retinoic acid or
vitamin D3. 44,45
Another major hypothesis puts the maturation state rather than a specific subset or loca-
tion of DC into the focus. These concepts do not necessarily exclude each other and some
propose that the immature state is the common factor after all. An anti-inflammatory
environment can promote an immature DC state. Moreover, it was also described that
DC in peripheral organs like the spleen are generally immature. 46
Activation or maturation of DC lead to a number of phenotypical changes including up-
regulation of MHC moleculres, co-stimulatory molecules, migratory factors like CCR7 and
the secretion of cytokines and chemokines. These alterations are important to mount a
protective inflammatory T cell response 47. Immature DC retain low expression of co-
stimulatory molecules resulting in insufficient T cell activation which in turn can lead
to tolerance. This classical view is however challenged by observations that DC with
increased expression of co-stimulatory molecules and CCR7 can be anti-inflammatory
leading to the term semi-mature DC 45,48–50. This indicates that insufficient T cell activa-
tion represents only one mechanism used by DC to induce tolerance.
DC modulate T cell responses via soluble mediators and via direct cell contact. The
most prominent anti-inflammatory cytokines secreted by DC are IL-10 51,52 and TGF-
β 53. But there are additional cytokines supporting tolerance, e.g. IFN-α is described to
synergise with IL-10 to downregulate T cell cytokines like IL-2 or IL-4 54 and IL-27 was
found to antagonise IL-2 transcription and to promote IL-10 secretion from different T cell
subsets 55. Furthermore, DC use soluble mediators influencing the metabolism of T cells.
Such metabolites include retinoic acid, a vitamin A derivate, 56 or indoleamine-pyrrole 2,3-
dioxygenase (IDO), which is a rate-limiting enzyme in the metabolism of tryptophane 57.
DC also regulate T cell activity in a contact-dependent manner. The B7 molecules PD-L1
and PD-L2 serve as co-inhibititory ligands 45. PD-L1, which was found to be upregu-
lated on tolDC 46, seems to play a more important role in this context. Blockade of
PD-1/PD-L1 interactions leading to a re-activation of the anti-tumour response revolu-
tionised cancer immunotherapy 58 and highlights the strong regulatory capacity of PD-L1.
5
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PD-1/PD-L1 or PD-L2 interaction are just one example of promoting tolerance via co-
inhibitory receptors on T cells. The co-stimulatory ligands CD80 and CD86 on DC can
also transfer inhibitory signals when interacting with CTLA-4. Furthermore, the family
of immunoglobulin-like transcript (ILT) receptors expressed on DC is implicated to pro-
mote T cell tolerance. As most of the other described co-inhibitory molecules, ILTs have
a dual function on both DC and T cells. In the case of ILT3, the tolerogenic phenotype
of the DC is stabilised by NF-κB inhibition while T cell proliferation can be suppressed
independently. 59,60 Although the molecular mechanism on T cells is not yet understood,
the suppressive function of ILT3 was clearly illustrated, e.g. by using soluble ILT3-Fc (in
the absence of DC) 61 or by the detection of increased serum concentrations of ILT3 in
patients with cancer or chronic infections 62,63.
1.2.2.2 Apoptotic cell-mediated tolerance
Around one million cells of the human body die every second due to physiological tis-
sue turnover and are rapidly cleared by phagocytes, e.g. Mφ and DC. 64 Apoptotic cells
are intrinsically immunosuppressive and hence their engulfment promotes a tolerogenic
phenotype and supports the presentation of self-antigens in a tolerogenic context. 65–67
The importance of apoptotic cells for peripheral tolerance was highlighted by the fact
that all mouse models harbouring defects in the clearance or processing of apoptotic cells
developed autoimmune disease 68–70.
Effects of apoptotic cells on Mφ were already described in 1997 by Voll et al. in co-
culture experiments. Pre-incubation of monocytes with apoptotic cells followed by LPS
stimulation resulted in reduced secretion of pro-inflammatory cytokines like IL-12 and
TNF-α when compared to monocytes only stimulated with LPS. Additionally, secretion
of the anti-inflammatory cytokine IL-10 was increased in pre-treated monocytes. Us-
ing cells from different species rendered apoptotic by different stimuli further suggested
a conserved anti-inflammatory function of apoptotic cells. 71 The capacity of apoptotic
cells to suppress inflammatory cytokine secretion from monocytes as well as from Mφ
was demonstrated in several other studies and some gave also further insight into the
underlying mechanisms 72–76. It was shown that apoptotic cell mediated suppression is
an immediate-early event which is independent of de novo protein synthesis 73 poten-
tially including enhanced transcription of suppressor of cytokine signaling (SOCS)1 and
SOCS3 76.
Similarly, inflammatory cytokine secretion from DC and upregulation of costimulatory
molecules and MHC II on the DC is impaired following pre-treatment with apoptotic
cells. 77–81 However, the secretion of IL-10 in response to apoptotic cells is controversial
for DC. 77,81,82 Regardless of IL-10, apoptotic cell treated DC show a rather tolerogenic
phenotype and a diminished ability to stimulate T cells.77–79
6
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1.2.2.3 T cell tolerance
Tolerogenic DC, as described above, are key regulators of peripheral tolerance, but the ul-
timate outcome of peripheral tolerance must be silencing of the adaptive immune system
against self. Autoreactive T cells in the periphery are controlled by three mechanisms:
deletion, anergy and Treg.
T cells undergo CD95- and Bim-mediated apoptosis following repeated TCR engagement
with pMHC. This process is important to limit T cell responses against pathogens but
also results in the elimination of autoreactive T cells since they encounter their antigen
frequently due to the expression within the own tissue. 83
Anergy is a state of T cell unresponsiveness that was first described by Rammensee and
colleagues in 1989 84. Anergic cells are long-lived and show no or only diminished prolifer-
ation and cytokine secretion. Importantly, not only the typically assessed TH1 cytokines
IL-2 and IFN-γ are reduced but there is no production of anti-inflammatory cytokines
such as IL-10 or TGF-β, either. 85–87 This phenotype is generally insusceptible to restim-
ulation but can be reversed by large amounts of exogenous IL-2 in vitro. The phenotype
seems to be more stable in vivo and resists IL-2 exposure but persistent presence of the
antigen is required to sustain unresponsiveness. 88,89
Anergic T cells are believed to develop upon suboptimal activation which mainly refers
to TCR stimulation in the absence of co-stimulation. 91,92 Additionally, immunomodulat-
ors like IL-10 were described to be involved in anergy induction in some cases. 93 Lack
of co-stimulation can be directly associated with inhibited IL-2 production. Full T cell
activation combines nuclear translocation of nuclear factor of activated T-cells (NFAT)
following TCR signalling induced calcium flux and nuclear translocation of activator pro-
tein 1 (AP-1) resulting from CD28 dependent protein kinase C (PKC)-θ (fig. 2). Trans-
location of both NFAT and AP-1 leads to IL-2 transcription, whereas signalling through
the TCR alone triggers only NFAT translocation and thereby transcription of a different,
rather inhibitory gene set. 90 The molecular mechanisms behind T cell anergy are not com-
pletely understood, yet it is generally accepted that the transcription factor early growth
response protein 2 (Egr2) and post-transcriptional modifications via ubiquitinylation are
essential. 87,94 Egr2 is an immediate target of NFAT and is found to be upregulated in
anergic T cells in vitro and in vivo. 95,96 Egr2 in concert with NFAT triggers an alternative
gene programme including Cblb, gene related to anergy in lymphocytes (GRAIL), cyclin
dependent kinase inhibitors and enhanced SOCS1 and SOCS3 activity. 29,97,98 Thus, Egr2
is an initiator of anergy.
Cblb is a E3 ubiquitin ligase that counteracts association of CD28 and PI3K by ubiquit-
inylation of the latter (fig. 2). As such, Cblb serves as a negative regulator that needs to
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cells. 109 Tr1 and TH3 cells are assumed to result from repetitive stimulation by tolDC in
the presence of IL-10 and TGF-β, respectively. 110,111
Despite the antigen-specific activation via the TCR, all Treg subsets suppress in antigen-
unspecific manner once they are activated. 107,108 CD25+FoxP3+ Treg exert their function
mainly via cell-cell contact but the details remain elusive. Aside from effects mediated
through Treg/effector T cell contact, CD25+FoxP3+ Treg modulate T cell responses in-
directly by interacting with DC. Treg might limit the contact of effector T cells to DC
due to increased expression of adhesion molecules and hence stronger binding to DC 112.
Another example for this indirect functions is the downregulation of costimulatory mo-
lecules (e.g. CD80) on DC via CTLA-4 on the Treg 113. The suppressive function of
induced Treg on the other side, relies mainly on contact-independent cytokine secretion.
Despite some studies linking Lag-3 expression to Tr1 cells, Tr1 cells are mainly defined
by the production of large amounts of IL-10 while TH3 primarily produce TGF-β.
110,111,114
Although T cell tolerance includes quite different mechanisms, namely deletion, anergy
and Treg, the criteria leading to their induction are very similar and even overlapping.
Antigen presentation in absence of inflammation or co-stimulation is described for both
Treg and anergic T cells 91,92,115,116. Moreover, tolDC are fundamental for all types of
tolerance and it seems that the distinct outcome of tolDC/T cell interaction is difficult
to predict. Hawiger and colleagues described that tolDC induced initial proliferation
followed mainly by deletion but also unresponsiveness of the remaining T cells after chal-
lenge 117. Furthermore, two similar models of tolerance using adoptively transferred T cells
resulted in different modes of tolerance. Kurts et al. observed T cell deletion of Ovalbu-
min (Ova)-specific T cells transferred into transgenic mice expressing Ova in pancreatic
cells 118, whereas Adler et al. observed anergy in influenza hemagglutinin (HA)-specific
T cells transferred into mice expressing HA on parenchymal cells 119. These studies clearly
indicate that there are further unknown factors that regulate the induction of different
modes of T cell tolerance and emphasise the complexity of peripheral tolerance.
1.3 Autoimmunity and tolerogenic therapy
About 1 in 15 individuals in developed countries is affected by autoimmune disease. In
these individuals misdirected immune responses attack healthy tissue leading to chronic
and sometimes even fatal pathologies. Autoimmune disease can be systemic like rheuma-
thoid arthritis and systemic lupus erythematosus or organ-specific as in the case of type 1
diabetes (T1D), or multiple sclerosis (MS). But in either case there is no cure and patients
need life-long treatment to control the disease. 120
Current therapies are based on general immunosuppression using corticosteroids or bio-
logics. The latter target different parts of the immune system like the inflammatory cy-
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tokines IL-6 (Tocilizumab) and TNF-α (Etanercept) or the complete B- and T-lymphocyte
compartment (Rituximab and Teplizumab, respectively). 120–122 These treatments are
rather unspecific and hence associated with numerous side effects. New therapeutic op-
tions that only inhibit the misguided immune response while sparing protective immunity
are urgently needed. Different approaches to achieve antigen-specific modulation of the
immune system are currently under investigation and described in the following sections.
1.3.1 Peptide therapy
Antigen presentation in the absence of inflammatory signals is generally thought to result
in tolerance. Thus, it seems straightforward to use soluble antigen for therapy.
Although administration of full protein was tested, current development is more focused
on using MHC trimmed epitopes. These include natural antigen peptides but also altered
peptide ligands, which are the predicted epitopes harbouring modifications of single amino
acids leading to an altered affinity to MHC or TCR. High doses of protein or peptide were
capable of inducing tolerance in different mouse models. 123–125 However, the outcome of
this type of therapy showed quite some variance and was even reported to induce ana-
phylactic responses. 123,126 Furthermore, attempts to translate peptide therapy into the
clinic failed due to a lack of efficiency or adverse affects. Peptides or full-length insulin
could so far not be proven to be an effective therapy in diabetes. 127,128 Altered peptide
ligands designed for MS were already quite advanced but could not pass phase 3 clinical
trials after all and even worsened the condition of some patients. 129–131
A different approach to deliver antigen is to trigger antigen expression in healthy organs
via DNA vaccination. While the risk of anaphylaxia can be reduced, reliable immunosup-
pression is also an critical issue of this approach. 123,132,133
1.3.2 Cell-based therapy
DC and Treg are important regulators of tolerance induction and maintenance. Using
or targeting these cells is therefore a promising concept for the treatment of autoim-
mune disease. Transfer of ex vivo expanded Treg populations had beneficial effects in
several mouse models of autoimmunity. 134–136 Clinical translation is however hampered
by phenotypic instability of ex vivo generated or expanded Treg observed after reinfu-
sion. 137,138 Nonetheless, Marek-Trzonkowska and colleagues recently reported encouraging
results from a phase I clinical trial suggesting a protective effect of Treg transfer in T1D
patients. 139 The positive outcome of this trial may have benefited from the fact that the
treated patients had just been diagnosed and hence it can be assumed that the trans-
ferred Treg faced a less inflammatory environment as compared to established disease.
This may have also been a reason for the reduced efficacy of a second Treg infusion after
the protective effects of the first infusion had faded 139.
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Shifting the focus from Treg transfer to DC therapy might circumvent the mentioned in-
stability problems since DC could induce and also maintain Treg populations directly in
vivo. tolDC can be exploited for treatment by generating tolDC populations loaded with
the desired antigen ex vivo. Antigen-pulsed DC can be rendered tolerogenic with a variety
of methods but immunosuppressive molecules (e.g. IL-10 or vitamin D3) or drugs (e.g.
rapamycin or dexamethasone) are most commonly used and ameliorated autoimmunity
in different mouse models. 41 The promising results from these animal studies encouraged
a number of clinical studies. The first proof of safety of tolDC in humans was reported
in 2011. In this trial, autologous monocyte-derived DC were tolerised with antisense oli-
gonucleotides against CD40, CD80 and CD86 and showed no adverse effects in diabetes
patients. 140 This study is now continued with a phase II study (NCT02354911). Further-
more, several phase I trials are ongoing in Crohn’s disease 141, rheumatoid arthritis 142,143
and MS using peptide-pulsed DC modulated with dexamethasone or vitamin D3 144.
Another approach to exploit tolDC-mediated immunosuppression is the use of apoptotic
cells which can serve as antigen delivery system and immunomodulator at the same time.
This idea was realised in the lab of Stephen Miller by coupling antigens to splenocytes
via 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (ECDI). The use of ECDI results in
apoptosis of the splenocytes and supports their localisation to the spleen where they are in-
gested by marginal zone Mφ. The antigen-loaded apoptotic splenocytes (Ag-SP) induced
prolonged tolerance that seems to rely on both anergy and Treg. 145,146 Ag-SP treatment
was able to control aberrant immune responses in mouse models of islet grafts, allergy,
MS and T1D. 145–148 Analogous to the generation of Ag-SP , autologous peripheral blood
mononuclear cells (PBMC) were coupled with seven different myelin peptides and tested
in a clinical phase I trial in MS patients. The study demonstrated a favourable safety pro-
file and even gave preliminary evidence for efficacy measured by reduced antigen-specific
T cell responses. 149
Erythrocytes are an interesting alternative vehicle. Billions of erythrocytes die every day
by eryptosis, which is comparable to apoptosis, as a consequence of natural turnover 150.
Thus, antigens attached to this cell population can be expected to be engulfed tolero-
genically in the context of eryptotic debris. Pishesha et al. coupled antigenic peptides
to erythrocytes ex vivo using sortase A. Transfusion of the engineered erythrocytes could
reduce disease burden in diabetic mice and experimental autoimmune encephalomyel-
itis (EAE), a mouse model of MS. 151 Erythrocyte physiology was further exploited even
without the need of cell transfer. The lab of Jeffrey Hubbell modified antigens to bind to
glycophorin A, which allows their binding to erythrocytes in situ. This targeting approach
triggered antigen-specific tolerance in an Ova and T1D model. 152,153
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1.3.3 Nanoparticle-based therapy
Cell therapies are individualised and show promising results, but their translation to the
clinic and to large patient cohorts is challenging. Mimicking apoptotic cells with synthetic
particles is a cell-free alternative that is easier to handle in a clinical setting. Nanoparticles
(NP) can be generated from different materials and their properties can be adapted to a
variety of applications and needs. This allows to incorporate multiple signals to deliver
complex messages to the immune system. NP are efficiently taken up which is attributed
to the fact that APC evolved to readily phagocytose and process particulate structures of
nano- and micrometer size like bacteria and viruses. Furthermore, association of antigens
with NP may circumvent the risk of anaphylaxia described for soluble peptide therapy by
limiting the concentration of free proteins or peptides in the circulation. 123,154
NP properties such as size and surface charge strongly influence their effect on the immune
system. Particle size is especially important for biodistribution. Particles smaller than
200 nm can move rather easily through blood and lymph and can reach spleen and lymph
nodes directly only hours after i.v. injection. In contrast, particles with a size larger than
200 nm up to some micrometers accumulate in the spleen but require internalisation and
active transport by APC to reach the lymph nodes. 123,154,155 Moreover, it was suggested
that smaller particles tend to be taken up by DC whereas larger particles are preferen-
tially engulfed by Mφ. 156 The surface properties of NP further impact biodistribution
and circulation half-life. An often undesired effect of hydrophobic particles is their recog-
nition by the reticulo-endothelial system (RES) which rapidly eliminates such particles
from blood circulation. Shielding the particle surface with the hydrophilic and non-ionic
polyethylene glycol (PEG) is commonly used to counteract interactions with the RES.
“PEGylation” can significantly increase the half-life in the circulation. 157 Apart from traf-
ficking, the surface charge influences also uptake and the type of response launched by the
APC. Cationic NP seem to be internalised to a higher extent due to interactions with the
negatively charged cell membrane 158,159 and are more associated with pro-inflammatory
responses 154,160. Anionic particles are less immunogenic and different groups managed to
induce tolerance using NP with a ζ-potential in the range of -40 to -70mV. 154,160–164
Different basic materials are used to generate tolerognic NP, namely metals, lipids and
polymers.
Yeste et al. designed gold particles loaded with antigen and the aryl hydrocarbon re-
ceptor (AhR) ligand ITE. By promoting Treg development these particles were able to
suppress EAE and diabetes 165,166. Another example for metal NP are iron oxide NP that
present disease-relevant pMHC complexes. pMHC I-NP were able to induce CD8+Tcell
tolerance and to control diabetes 167 while pMHC II-NP were demonstrated to provoke
Tr1 responses that were beneficial in different mouse models 168. Notwithstanding that
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pMHC-NP are a sophisticated approach, clinical translation will be difficult since detailed
knowledge of relevant antigen epitopes and broadly usable MHC alleles is necessary. And
moreover, metal NP cannot be fully degraded and accumulation might cause toxicities.
Liposomes are a well-known delivery system that can be trimmed by its phospholipid
composition. The composition impacts basic properties like loading and uptake but can
also be used for functionalisation. 154 PS is characteristically expressed on the surface of
apoptotic cells and thus might support tolerance. 64,65 This feature was utilised to generate
peptide-loaded PS liposomes that protected mice from developing diabetes. 169
Polystyrene particles (also known as latex beads) are often used in early experimental
studies since they are comparably easy to handle. As such, Getts et al. illustrated that
negatively-charged, peptide-coupled polystyrene particles can prevent EAE and reduce
disease burden. Interestingly, only 500 nm particles but not larger particles (1.75µm and
4.5µm) induced convincing immunosuppression. 170
A more feasible polymer which is also suitable for clinical use is poly(lactic-co-glycolic
acid) (PLGA). PLGA is biodegradable in the sense that it can be hydrolised to the nat-
ural metabolites lactic acid and glycolic acid and has a good safety profile. The formula-
tion of PLGA-NP can be adjusted for different types of drugs and different drug release
kinetics. 171–174 Thus, PLGA is approved by the FDA and EMA as drug delivery system
in a couple of clinical applications. 175 Concerning the treatment of autoimmune disease,
PLGA-NP with different properties, coating and loading are explored in preclinical stud-
ies. NP can contain immunomodulators in addition to the antigen to ensure a tolerogenic
outcome. A rather stable approach is the encapsulation of antigen in combination with
the mTOR inhibitor rapamycin. EAE was inhibited by NP combining rapamycin with
either peptide or protein administered via different routes. Even when co-administered
with Tol- like receptor (TLR) 7/8 agonists, these NP kept their immunosuppressive ca-
pacity. 176–178 Nevertheless, rapamycin is a drug with several adverse effects. These side
effects might be reduced to some extent by encapsulation and hence restriction to cer-
tain cell populations, but in general the tolerogenic delivery of antigen without the need
for additional drugs seems more appealing. More physiological immunomodulators could
be one alternative to rapamycin. Roberts et al. ameliorated EAE by attaching PS to
the surface of peptide-loaded NP in adaptation to apoptotic cells 179 and others incorpor-
ated recombinant IL-10 into the NP to achieve similar results 180. Besides, it might even
be possible to use antigen alone. Intravenous administration of negatively-charged NP
loaded with antigen alone was sufficient to transfer antigen-specific tolerance in models
of MS, T1D and graft rejection. 160–164,170,181,182 The potential mechanisms employed by
these NP include specific targeting to marginal zone Mφ but also conveying a tolerogenic
phenotype to both Mφ and DC resulting in anergy as well as Treg induction. However,
the comprehensive mechanism for the observed immunosuppression is not yet clarified.
Especially in the light of studies that showed no suppressive capacity 176 or even immun-
13
1 Introduction
ogenic responses 183–186 to NP with antigen alone, it is important to define the distinct
NP properties preceding the divergent outcomes. Although the underlying mechanism is
not fully elucidated, this type of antigen-associated carboxylated NP is now tested in a
phase I clinical trial for celiac disease (NCT03486990). In this context, the NP are termed
tolerogenic immune-modifying particles (TIMP) and are loaded with the antigen gliadin
1.4 Annexins
The superfamily of annexins consists of thirteen members with one pseudogene (an-
nexinA12) amongst them that does not result in a translated protein. The C-terminal
part of annexins consists of four similar repeats and includes Ca2+ binding sites. Regard-
less of only 45-55% amino acid identity, the core domain is evolutionary conserved with
respect to its secondary and tertiary structure. In contrast, the N-terminal domain is
unique to each family member. 187
Annexin A1 (AnxA1) was initially described as a mediator in glucocorticoid responses
assisting the resolution of inflammation. 188–190 Beyond this intracellular effect, it is now
known that AnxA1 can also act as an extracellular mediator. Under steady state condi-
tions AnxA1 resides in the cytosol. However, upon apoptosis it is translocated to the cell
surface with kinetics similar to those of PS 80,191 suggesting a broader immunosuppressive
role.
Many regulatory functions were attributed to the N-terminus of AnxA1 which is cleaved
by extracellular proteases following externalisation which gives rise to a number of dif-
ferently sized peptides. 192–195 These peptides can serve as chemoattractants for phagocytes
and also enhance their phagocytic function. 196,197 Furthermore, the AnxA1 N-terminus
was identified as ligand for the formyl peptide receptor (FPR)1 and FPR2 and as such to
inhibit monocyte and neutrophil function and migration. 198,199
Although most research on the anti-inflammatory function of AnxA1 focused onf FPR sig-
nalling, AnxA1 can also exert inhibitory functions via a second, FPR-independent mech-
anism. Full-length AnxA1 in the presence of FPR inhibitors or the AnxA1 core domain (Anx)
alone transfer a tolerogenic phenotype to APC. 80,82,200
AnxA1 was recognised as immune regulator, but AnxA1−/− mice show no signs of spon-
taneous autoimmunity. Redundancy between the members of the annexin family may
be the reason for the inconspicuous phenotype. AnnexinA5 and annexinA13 are trans-
located to the surface of early apoptotic cells and modulate DC maturation similar to
AnxA1. 82,201,202 Above all, the suppressive capacity of AnxA1 on DC could be attributed
to the conserved core domain. 80,82 Thus, general function of annexins as mediators of the
apoptotic cell intrinsic immunosuppression can be assumed.
Besides the broad acceptance of AnxA1 being inhibitory at the level of APC, the effects on
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T cells are controversial. AnxA1 deficient T cells were described to be both hypo- 203 and
hyperproliferative 204. Moreover, the induction of inflammatory conditions in AnxA1−/−
mice also yielded contradictory results. 204–206 Delineating the effects of AnxA1 in vivo is
complicated since yet unknown T cell-intrinsic AnxA1 effects can neither be ruled out nor
separated from direct or indirect (APC-mediated) extracellular effects on T cells.
In humans, there are no known correlations of genetic defects in annexins that are caus-
ative for disease. This may be due to redundant function of annexins and the unlikeliness
of spontaneous mutations in all or several annexins.
Nonetheless, increased levels of AnxA1 cleavage products were found in patients with
fragile X syndrome, Weber-Christian disease, familial Mediterranean fever, cystic fibrosis
and other lung diseases 192,207–209 whereas diminished serum levels of AnxA1 were reported
for patients with uveitis and MS 206,210. Furthermore, α-AnxA1 autoantibodies were detec-
ted in patients with rheumatoid arthritis, inflammatory bowel disease and systemic lupus
erythematosus but so far no correlation with disease severity could be established. 211–214
α-AnxA1 autoantibodies may actually be a simple by-product generated in course of the
disease. Neutrophil extracellular traps (NET) are normally a mechanism of innate immune
defence. However, they are also associated with the production of α-DNA autoantibod-
ies and aberrant protein modification. AnxA1 has been found to be abundant in NETs
where it is also citrullinated. Citrullinated proteins are common targets of autoantibodies
in several autoimmune disease, so AnxA1 does not seem to have a disease-related role in
this context. 215
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1.5 Aim of the study
Apoptotic cells have intrinsic anti-inflammatory properties and maintain peripheral tol-
erance. Engulfment of apoptotic cells results in an immunologically silent presentation
of their cargo by inducing an inhibitory phenotype in the phagocyte. Since apoptotic
cells of an healthy individual mainly comprise self-antigens, this process is essential to
avoid autoimmune reactions. However, the underlying mechanisms by which apoptotic
cell-mediate immunosuppression are still largely unknown.
Our group previously found that several members of the annexin protein family are trans-
located to the surface of early apoptotic cells and hypothesised that the evolutionary
conserved annexin core domain (Anx) is a mediator of apoptotic cell-mediated tolerance.
Recombinant Anx antagonises Toll-like receptor signalling and impairs DC activation.
Hence, Anx is a potential tool to induce immunosuppression in an antigen-specific man-
ner. Current therapies for autoimmune disease universally dampen the immune system
and are thus accompanied by severe side effects. Restricting the suppressive treatment to
the relevant self-antigens and inhibiting self-reactive immune responses by an endogenous
mediator such as Anx could improve tolerability in patients suffering from autoimmune
disease.
The aim of this study is to develop a vehicle that combines an antigen of interest and
Anx to allow the delivery of the antigen in a tolerogenic context. We hypothesise that the
combination of Anx with an antigen in a particulate structure induces antigen-specific
immunosuppression. In order to test this hypothesis, Anx and the model-antigen Ova
were coupled to polystyrene beads and PLGA nanoparticles. This study investigated the
ability of the Anx-coated particles to affect DC phenotype and to modulate Ova-specific
T cell responses. Furthermore, the function of Anx-coated particles was compared to sol-
uble Anx and its known tolerogenic properties.
In summary, this study aims to develop a particle-based delivery system using Anx to
promote antigen-specific tolerance and to investigate the underlying mechanisms of Anx-
induced tolerance.
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2 Materials
2.1 Chemicals and Reagents
2.1.1 Chemicals
Chemicals were purchased from Serva, Sigma-Aldrich or Roth.
2.1.2 Reagents
Reagent Company
7AAD Sigma-Aldrich
AKP BD Becton Dickinson GmbH
Alexa Fluor 546 Phalloidin Life Technologies
BCIP/NTP Sigma-Aldrich
CFSE Sigma-Aldrich
CpG ODN 1668 Biomol
DCFDA Life Technologies
dNTPs (10 mM) Life Technologies
DPBS Life Technologies
Western Lightning Plus-ECL PerkinElmer
FluoSpheres Sulfate Microspheres, 1µm Life Technologies
GeneAmp 10x PCR Buffer and MgCl2 Life Technologies
Hoechst 34580 Life Technologies
MulV reverse transcriptase (50U/µl) Life Technologies
PageRuler Plus Prestained Protein Ladder Thermo Scientific
PMA Sigma-Aldrich
Poly(I:C) InvivoGen
Power SYBR Green PCR Master Mix) Applied Biosystems
RNAse Inhibitor (20U/µl) Life Technologies
Trolox Th. Geyer
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2.1.3 Commercial Kits
Kit Company
EasySep Mouse CD4+ T Cell Isolation Kit STEMCELL Technologies
FoxP3 Fixation/ Permeabilization Kit eBioscience
mouse IL-6 OptEIA ELISA Set BD Becton Dickinson GmbH
mouse IL-2 OptEIA ELISA Set BD Becton Dickinson GmbH
mouse IFN-γ OptEIA ELISA Set BD Becton Dickinson GmbH
Murine IL-12 Standard ABTS ELISA Kit PeproTech
RNAqueous-Micro Total RNA Isolation Kit Thermo Scientific (Ambion)
2.2 Buffers and solutions
Buffer/Solution Composition
ACK buffer pH 7.2
150 mM Ammoniumchloride (NH4Cl)
10 mM Kaliumhydrogencarbonate
(KHCO3)
1 mM EDTA
ddH2O
Blocking buffer (Western blot)
5 % (w/v) skim milk powder
TBS-T
Citrate buffer 0.1 M pH 5.0
30 mM citric acid monohydrate
70 mM natrium citrate dihydrate
ddH2O
Coating buffer pH 9.6 (BD
ELISA)
100 mM Natriumhydrogencarbonate
(NaHCO3)
34 mM Natriumcarbonate (Na2CO3)
ddH2O
ELISA wash buffer
0.05 % (v/v) Tween 20
TBS
FC buffer
10 % (v/v) rat serum
10 % (v/v) FCS
PBS
OPD
50 ml Citrate buffer
1 OPD tablet
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Phosphate Buffered Saline
PBS pH 7.4
137 mM Natriumchloride (NaCl)
8.1 mM Dinatriumhydrogenphosphate
(Na2HPO4)
2.7 mM Kaliumchloride (KCl)
1.5 mM Kaliumdihydrogenphosphate
(KH2PO4)
ddH2O
PBS-T
0.05 % (v/v) Tween 20
PBS
Reducing Sample buffer 5x
for Western Blot
50 % (v/v) glycerol
25 % (v/v) β -Mercaptoethanol
10 % (w/v) SDS
50 mM Tris pH 6.8
0.25 mg/ml bromphenol blue
ddH2O
Resolving Gel (SDS-PAGE)
24 mM Tris-HCl pH 6.8
5 % (w/v) acrylamide
0.1 % (w/v) SDS
0.1 % (w/v) APS
0.1 % (v/v) TEMED
dH2O
SDS Running Buffer
25 mM Tris
0.19 M Glycine
1 % (w/v) SDS
dH2O
Semi Dry Transfer Buffer pH 9.2
48 mM Tris
39 mM Glycine
0.04 % (w/v) SDS
10 % (v/v) Methanol
ddH2O
Stacking Gel (SDS-PAGE)
37.5 mM Tris-HCl pH 8.8
10 % (w/v) acrylamide
0.1 % (w/v) SDS
0.03 % (w/v) APS
0.1 % (v/v) TEMED
dH2O
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Stemcell buffer
1mM EDTA
2 % (v/v) FCS
PBS
Tris-buffered Saline TBS pH 7.5
50 mM Tris-HCl pH 7.5
150 mM NaCl
dH2O
TBS-T
0.05 % (v/v) Tween 20
TBS
Trypan blue 0.4 %
0.4 % (w/v) Trypan blue
0.1 % (v/v) Natriumazide
PBS
2.3 Culture Media and Supplements
Medium/Supplement Company/Composition
DC medium RPMI 1640, 10% FCS, 20 ng/ml rmGMCSF
ELISpot medium RPMI 1640, 1% PenStrep, 2% mouse serum
Fetal Calf Serum (FCS) Sigma-Aldrich
Mouse Serum Linaris
Penicillin Streptomycin 10’000U/ml Life Technologies
Polymyxin B Abcam
Rat Serum Milteny Biotec
rmGMCSF Immunotools
RPMI 1640 Medium Sigma-Aldrich
1% medium RPMI 1640, 1% (v/v) FCS
10% medium RPMI 1640, 10% (v/v) FCS
2.4 Biologic material
2.4.1 Cell lines
Name Description
JE6.1 human T cell line (ATCC TIB-152)
2.4.2 Mouse strains
Name Description
C57BL/6C57 C57 Black 6 (wild type)
OT-II B6.Cg-Tg(TcraTcrb)425Cbn/J
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2.5 Antibodies
If not stated otherwise all antibodies are directed against mouse proteins.
2.5.1 ELISpot Antibodies
Antibody Use Dilution Company
α-IL-2 capture 1:200 BD Becton Dickinson
α-IL-2-Biotin detection 1:250 BD Becton Dickinson
2.5.2 Labelled Antibodies
Antigen target Fluorophore Clone Dilution Provider
Anx1 APC mAx550 1:500 Heiko Weyd, DKFZ
CD4 APC-Cy7 GK1.5 1:200 Biolegend
CD4 PE H129.19 1:200 BD Pharmingen
CD11c APC N418 1:150 Biolegend
CD40 PE 3/23 1:150 Biolegend
CD40 PE-Cy7 3/23 1:150 Biolegend
CD44 PE-Cy7 IM7 1:150 Biolegend
CD69 APC H1.2F 1:150 Biolegend
CD73 APC TY/11.8 1:150 Biolegend
CD80 FITC 16-10A1 1:150 eBioscience
CD85k (ILT3) PE H1.1 1:150 Biolegend
CD86 FITC GL1 1:150 eBioscience
CD90.1 (Thy1.1) PE OX-7 1:200 BD Pharmingen
CD90.1 (Thy1.1) PerCP-Cy5.5 OX-7 1:200 Biolegend
CD157 (CTLA-4) PE-Cy7 UC10-
4B9
1:150 Biolegend
CD223 (Lag3) APC C9B7w 1:150 Biolegend
CD273 (PD-L2) FITC 122 1:150 eBioscience
CD274 (PD-L1) PE-Cy7 10F.9G2 1:150 Biolegend
CD275 (ICOSL) PE HK5.3 1:150 Biolegend
CD279 (PD-1) PE-Cy7 RMP1-30 1:150 Biolegend
CD366 (Tim-3) PE B8.2C12 1:150 Biolegend
FoxP3 APC FJK-16s 1:50 eBioscience
FR4 PE 12A5 1:150 Biolegend
I-A/I-E(MHC-II) PerCP-Cy5.5 M5/114.
15.2
1:150 eBioscience
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2.5.3 Western Blot Antibodies
Antibody Dilution Provider
mouse α-Anx1 (mAx550) 1:1000 Heiko Weyd, DKFZ
mouse α-Flag M2 1:10,000 Sigma-Aldrich
mouse α-Ova 1:1000 Santa Cruz
goat α-mouse-IgG-HRP 1:10,000 Santa Cruz
goat α-mouse-IgG2b-HRP 1:10,000 Southern Biotech
2.5.4 Stimulation Antibodies
Antigen target Clone Dilution Company
CD3e 1 45-2C11 1:400 BD Biosciences
CD28 E18 1:400 BioLegend
CD40 FGK4.5 BioXcell
2.6 Proteins, Peptides and Oligonucleotides
2.6.1 Proteins
Protein Provider
murine annexin core domain (Flag-tagged) Fatmire Bujupi, DKFZ
DQ-Ovalbumin Life Technologies
EndoGrade Ovalbumin Hyglos
2.6.2 Peptides
Peptide name Protein sequence Company
ISQ ISQAVHAAHAEINEAGR InvivoGen
SIINF SIINFEKL eBioscience
SIY SIYRYYGL Peptide Specialty Laboratories
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2.6.3 qPCR Primer
Gene
target
Forward Primer 5’→ 3’ Reverse Primer 5’→ 3’
Cblb ATGTCCCTCCTCGGCTTT GAGACAATTTGCTAATGGACCAG
Egr2 GCCAAGGCCGTAGACAAAATC CCACTCCGTTCATCTGGTCA
GRAIL AATTTCACGGTGCCCACGGTTTGG ATTGCAACAATGTCCCCAGACCC
HMBS GAGTCTAGATGGCTCAGATAGCATGC CCTACAGACCAGTTAGCGCACATC
HPRT GAGGAGTCCTGTTGATGTTGCCAG GGCTGGCCTATAGGCTCATAGTGC
IDO GCCTCCTATTCTGTCTTATGCAG CGAGGAAGAAGCCCTTGTC
IL-2 AAAAGCTTTCAATTGGAAGATGCT TTGAGGGCTTGTTGAGATGA
IL-27p28 CTGTTGCTGCTACCCTTGCTT CACTCCTGGCAATCGAGATTC
Maf AGCAGAAGAGGCGGACCCTGAAAA GCCGTTGCTCACCAGCTTCTCGTATT
SOCS1 CTGCGGCTTCTATTGGGGAC AAAAGGCAGTCGAAGGTCTCG
SOCS3 ATGGTCACCCACAGCAAGTTT TCCAGTAGAATCCGCTCTCCT
2.7 Consumables
Consumable Company
BD Trucount tubes BD Becton Dickinson GmbH
Cell culture plates and dishes TPP
Costar R© ELISA Plate 96 well Corning
clear flat bottom half area,
high binding polystyrene
Costar R© 50 ml reagent reservoir Corning
EASYstrainer 40 µm sterile Greiner Bio-one
FACS tubes BD Becton Dickinson GmbH
IP clear plates 0.45 µl MSIPS4510 Merck Millipore
hydrophob high protein binding
immobilion-P membrane sterile
LoBind microcentrifuge tubes Eppendorf
Nitrocellulose membrane GE Healthcare
Amersham Protran 0.45 NC
Lab-Tek Chamber Slide, 8 wells, Permanox Sigma-Aldrich
PCR tubes, flat lid, 100 µl Starlab
Reaction tubes 1.5 ml/2 ml Eppendorf
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2.8 Instruments
Instrument Company
CTL ImmunoSpot Reader Cellular Technology Limited
FacsCanto II flow Cytometer BD Becton Dickinson
GloMax-Multi Detection System Promega
Chemi-Smart 5100 Peqlab
Microplate Reader Model 680 BioRad
Microplate Washer 405 TS BioTek Instruments
Microscope brightfield Carl Zeiss Microscopyy
Molecular Imager GelDoc XR+ BioRad
NanoDrop ND-1000 spectrophotometer Peqlab
pH meter ProfiLine pH 3210 WTW
PowerPac HC Biorad
Thermal Cycler C1000 BioRad
Thermomixer Comfort Eppendorf
Trans-Blot R© SD Semi-Dry Transfer Cell BioRad
UV-Stratalinker Stratagene
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2.9 Software
Software Company
ChemiCapt 5000 Imaging Software Vilber Lourmat
FacsDiva BD Becton Dickinson
Flow Jo FlowJo LLC
GraphPad Prism version 6 GraphPad Software
ImageJ (Fiji) Wayne Rasband, NIH
ImmunoSpot SC Suit Cellular Technology Limited
LATEX Leslie Lamport, LaTex Project Team
Microplate Manager version 5.2.1 BioRad
Microsoft Office Microsoft
Zen 2012 version 8.1 Carl Zeiss Microscop
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3.1 Organ and cell Isolation
3.1.1 Bone marrow-derived dendritic cells - BMDC
Leg bones (tibia and fibia) of wt mice were dissected and bone marrow was flushed into
PBS. The bone marrow cells in the suspension were then separated from other tissue
by filtering through a 40µm strainer. The cells were pelleted for 5min at 1500 rpm and
4 ◦C and then resuspended in 3ml ACK-buffer to lyse remaining erythrocytes. After 40 s
the reaction was stopped by adding 40ml 10%medium. Following a washing step with
10%medium, the cells were counted and adjusted to 0.5 x 106/ml in DC medium and
seeded into a 24-well plate (1ml/well). Bone marrow cells are differentiated into DC in
DC medium over 7 d. DC medium was fully replaced with fresh medium after 2 days and
partly replaced (500 of 1000µl) after 4 days of differentiation.
3.1.2 Splenocytes and CD4+ Tcells
Spleens from OT-II mice were harvested and mashed through a 40µm strainer. The cells
were pelleted for 15min at 1500 rpm and 4 ◦C and then resuspended in ACK-buffer to
lyse remaining erythrocytes. After 1.5min the reaction was stopped by filling up with
10%medium. After centrifugation (15min, 1500 rpm, 4 ◦C) splenocytes can be resus-
pended in 10% medium for preactivation or in Stemcell buffer for further CD4+Tcell
isolation.
CD4+Tcell were isolated using the EasySep mouse CD4+Tcell isolation kit according to
manufacturer’s protocol. In brief, 1 x 108/ml splenocytes were incubated for 10min with
50µl rat serum and 50µl negative selection cocktail per ml cell suspension. Then, 75µl
isolation beads per ml cell suspension were added. After 2.5min the solution was filled
up to a total volume of 10ml with Stemcell buffer. The tube was placed into a EasySep
magnet to separate T cells from other cells in the suspension. The cleared T cell solution
was transferred to a new tube.
Subsequently, T cells were labelled with CFSE. First, cell suspension was adjusted to
2 x 107/ml in PBS and mixed with an equal volume of CFSE solution (1:15000 in PBS).
Following 20min incubation in the dark, the staining reaction was stopped by adding
one volume of FCS. After 2min at RT, the tube was filled up with ice cold 10%medium
and incubated for another 5min on ice. Finally, the cells were washed 2 times with
1%medium.
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3.2 Cell Biology
3.2.1 Apoptosis induction
Apoptotic cells were generated by seeding 1 x 106/ml JE6.1 in a 6-well plate with a total
volume of 2.5ml/well and irradiation with 75µJ UV-C. Irradiated cells were incubated
at 37 ◦C for at least 2.5 h before they were used in further assays.
3.2.2 BMDC suppression assay
BMDC which were differentiated for 7 days were seeded in a 96-well plate (flat-bottom) at
0.75 x 105 cells/well in 175µl 1%medium supplemented with polymyxin B (PmxB) (final
conc. 50µg/ml). PmxB was added to avoid unspecific TLR4 stimulation by LPS and
to rule out endotoxin tolerance. After 1 h resting at 37 ◦C, 50µl treatment (e.g. Anx
or beads) were added. In the case of apoptotic cell treatment, 3 x 105 apoptotic JE6.1
(aJ) were added 5 h after BMDC seeding. BMDC are incubated with treatments for 8 h
(4 h for aJ) and then stimulated with 25µl CpG (final conc. 20 nM). The response of
BMDC to the different treatments was analysed by flow cytometry (FC), gene expression
(qRT-PCR) and cytokine secretion (ELISA) on day 1 or day 2 after stimulation.
3.2.3 T cell suppression assay
For the analysis of T cell responses, BMDC were differentiated and treated as described in
3.1.1 and 3.2.2. On day 2 after BMDC stimulation, 0.5 x 106 CFSE labelled CD4+ Tcells
were added per well. The preparation and staining of CD4+ Tcells from OT-II mice
is described in 3.1.2. Following 2 days of co-culture, 60µl/well supernatant were taken
for IL-2 analysis and substituted with fresh 1%medium. After a total of 5 days of co-
culture, the media including the T cells was transferred into a round-well 96-well plate
and centrifuged at 10min at 1500 rpm. The supernatants were used to measure IFN-γ
secretion while the cell pellet was further processed for FC analysis.
3.2.4 T cell preactivation
Spleens from OT-II mice were prepared as described in 3.1.2. Splenocytes were then
seeded in a cell culture flask at a concentration of 1 x 107/ml in 10%medium and stim-
ulated with α-CD3 [1µg/ml] and α-CD28 [0.5µg/ml]. After over night incubation with
the stimulatory antibodies, cells were washed and transferred to a new flask with fresh
10%medium. Splenocytes were then rested for another 3 days, with addition of further
fresh media if necessary, before CD4+ Tcells were isolated as described in 3.1.2. The ac-
tivation status of the T cells was monitored by measuring the expression of CD69, CD44
and CD62L via FC before and after stimulation as well as after T cell isolation.
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3.2.5 ROS assay
BMDC, differentiated for 6-7 days were seeded in a 48-well plate (flat-bottom) with
1 x 105 cells/well in 1%medium supplemented with polymyxin B (final concentration:
50µg/ml). After 1 h incubation at 37 ◦C, the treatment (e.g. Anx or Beads) or the
positive control PMA [10 ng/ml] was added. Following 1.5 h of incubation with the treat-
ment, the ROS-sensitive dye DCFDA was added in a final concentration of 5µM. After
a total of 2 h of treatment including 30min DCFDA incubation, the cells were harvested
by rinsing the wells and transferring the cell suspension into tubes or a round-bottom
96-well plate, to facilitate pelleting by centrifugation. From the harvesting step onwards,
cells need to be kept on 4 ◦C to avoid further (unspecific) ROS production. Optionally
the cells can be incubated with the ROS scavenger Trolox [final conc 25µM] for 10min
before harvesting, to further exclude unspecific ROS production. The harvested cells
were pelleted (5min, 1500 rpm (plates) or 5000 rpm (tubes)), washed once with PBS and
finally resuspended in FC buffer (optionally including Trolox). ROS production was then
measured by assessing the fluorescent signal of processed DCFDA by FC.
3.2.6 DQ-Ovalbumin Assay
Antigen processing was analysed using a commercially available Ova that is labelled with
a processing sensitive dye (DQ-Ova). BMDC were seeded and treated as described in
3.2.2. The treatment included soluble DQ-Ova and Beads coupled with DQ-Ova instead
of unlabelled Ova. For each experiment, two similar plates were prepared in order to
incubate one plate at 4 ◦C as background control while the other one was incubated at
37 ◦C to allow uptake and processing. After 4 h incubation, cells were harvested and
analysed via FC.
3.3 Molecular Biology
3.3.1 Immunoassays
3.3.1.1 Enzyme Linked Immunosorbent Assay - ELISA
Generally, ELISA was performed according to manufacturer’s protocol. This brief de-
scription is referring to the BD OptEIA kits.
Half-area plates were coated with 50µl capture antibody solution per well and incub-
ated over night at 4 ◦C. Plates were washed 3 times with TBS-T and then blocked with
100µl PBS/10%FCS for 1 h at RT. After blocking, plates were washed 3 times and 50µl
assay supernatant (if necessary diluted in PBS/10%FCS) were loaded in duplicates for
2 h at RT. Following 5 times washing, 50µl of detection antibody solution including strep-
tavidin were added to the wells and incubated for 1 h. Plates were then washed 7 times
and incubated with developing solution (OPD + H2O2 (1:1000)) in the dark. The colour
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reaction was stopped with 25µl 3NH2SO4 when desired intensity of the highest standard
sample was reached. Cytokine secretion represented by colour intensities was measured
at 490 nm absorbance with a microplate reader (BioRad).
3.3.1.2 Enzyme Linked Immunospot Assay - EliSpot
Membranes of the ELISpot-plates were activated by short incubation with 50µl 70%EtOH.
Plates were washed with 200µl PBS and then incubated with 100µl coating antibody in
PBS at 4 ◦C over night. After washing with PBS, the plates were blocked with ELISpot-
medium at 37 ◦C for at least 1 h. After blocking, splenocytes in ELISpot-medium were
seeded into the plate with 1.5 x 106/well. The cells were then stimulated with peptides
[2µM] or stimulation antibodies [50µg/ml] over night. On the following day, the super-
natants were taken and stored for additional ELISA. The plate was washed 5 times with
PBS-T and once with PBS before 100µl detection antibody in PBS was added and incub-
ated for 2 h at RT. The plate was washed again 4 times with PBS and 100µl Streptavidin-
AKP solution (1:500 in PBS) was added for 30min. Following 4 washes with PBS the
plate was developed for 3min in the dark using 100µl BCPT/NBT solution. The de-
veloping reaction was stopped by rinsing the plate with dH2O. The plate was dried and
analysed using ImmunoSpot CTL machine and software.
3.3.1.3 Flow cytometry - FC
For the analysis of surface molecules, cells were first blocked for 10min in FC buffer and
then incubated with the desired mixture of labelled antibodies for 20min on ice. After
washing with PBS/10%FCS, the cells could be analysed by flow cytometry or further
processed for additional intracellular staining.
Intracellular staining of FoxP3 was performed using the eBioscience fixation and permeab-
ilisation kit according to manufacturer’s protocol. Briefly, surface stained cells were fixed
for 20min with Fix/Perm buffer followed by one washing step with PBS and two washing
steps with permeabilisation buffer. Cells were then incubated for 15min in permeabilisa-
tion buffer containing 2% rat serum and subsequently α-FoxP3-PE was added for 25min.
Afterwards, the cells were washed with permeabilisation buffer and then resuspended in
FC buffer. During and after staining, cells were kept at 4 ◦C.
3.3.1.4 Microscopy
BMDC which were differentiated for 6 days were seeded in a 8-well chamber slides
at 9 x 104 cells/well in 200µl 1%medium supplemented with polymyxin B (final conc.
50µg/ml). After 1 h resting at 37 ◦C, 50µl beads [7.5 x 106/ml] were added. BMDC were
incubated over night with the beads before they were fixed and stained for microscopy.
For the staining, cells were rinsed with PBS and then fixed for 15min at RT with 4% para-
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formaldehyde. Following washing with 1ml PBS, cells were then permeabilised by 10min
incubation in 0.1%TritonX-100 and afterwards washed with PBS. Cells were blocked
in 2%BSA in PBS over night at 4 ◦C . After washing with PBS, cells were stained with
Hoechst and Phalloidin (1:400 in 2%BSA/PBS). The stained cells were washed with PBS
and embedded with Mowiol.
3.3.1.5 Western Blot
Western blot was used to analyse the binding of Ova and Anx to the surface of latex
beads. In order to elute proteins from the bead surface, beads were boiled at 95 ◦C
in reducing sample buffer for 15min. The protein elution was subjected to SDS-PAGE
(10% gels run at 120V). Separated proteins were blotted onto a nitrocellulose membrane
in a BioRad Trans-blot semi-dry cell for 30min at 15V. Membranes were then shortly
washed with TBS-T and blocked with 5%milk powder in TBS-T for at least 30min. For
protein detection, membranes were incubated with primary antibodies (diluted in TBS-
T/1%BSA/N3) over night at 4
◦C followed by 3 times 5min washing with TBS-T and 1 h
incubation with the secondary antibody at RT. After another 3 times 5min washing with
TBS-T the membrane was developed using ECL detection reagent and recorded with the
Chemi-Smart 5100 System.
3.3.2 mRNA quantification
3.3.2.1 RNA preparation
RNA was extracted using the ambion RNAqueous micro kit following manufacturer’s
protocol. In short, cell pellets were lysed by vortexing in 100µl lysis buffer. After adding
50µl EtOH, the lysates were transferred to the provided columns and centrifuged for 15 s
at 13000 rpm, 4 ◦C. The column membranes were washed once with 180µl wash solution I
and twice with 180µl wash solution II. The membranes were then dried by centrifugation
for 1min at 13000 rpm, 4 ◦C. Deviating from the recommendation of the manufacturer,
RNA was eluted in a total volume of 15µl in two rounds from membranes using preheated
elution buffer (75 ◦C). RNA concentration was determined by spectrophotometry.
3.3.2.2 Quantitative Real-Time PCR - qRT-PCR
For gene expression analysis, 500 - 800µg RNA was reverse transcribed into cDNA by
mixing 11.7µl RNA solution with 14.3µl mastermix as shown in tab. 1 and performing a
PCR with the programme shown in tab. 2.
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Table 1: RT-PCR Mastermix 1x master
mix for RT-PCR
Component Volume
MgCl2 [25mM] 5.2µl
10 x PCR Buffer 2.6µl
dNTPs [10mM] 2.6µl
OligodT [100 pmol/µl] 1.3µl
RNAse Inhibitor [20U/µl] 1.3µl
MulV transcrpitase [50U/µl] 1.3µl
Table 2: RT-PCR programme
PCR programme for RT-PCR
Temperature Time
25 ◦C 10min
42 ◦C 45min
95 ◦C 5min
8 ◦C ∞
For the qPCR (programme see tab. 3), the cDNA (2µl) was added to a mix of 7.5µl
SYRB green master mix, 1.5µl primer mix [5µM stocks] and 4µl H2O. Gene expression
was evaluated using ∆∆Ct method.
Table 3: qPCR programme PCR programme for qPCR
Temperature Time
50 ◦C 2min
60 ◦C 10min
95 ◦C 15 s
40 x
60 ◦C 1min
3.4 in vivo experiments
For the analysis of Ova-specific responses in vivo, OT-II T cells (2 x 106/mouse) were
prepared and labelled as described in 3.1.2 and then i.v. injected into wt mice. On
the following day (d0) mice were treated with beads or controls by i.v. injection. Six
days after treatment, mice were sacrificed and spleens and in some cases lymph nodes
were isolated analogous to 3.1.2. Both splenocytes and lymphocytes were analysed by FC
while only splenocytes were plated and restimulated for cytokines analysis (see 3.3.1).
3.5 Particles
3.5.1 Bead preparation
Here, only the final and optimised protocol is described. More details and differential
conditions are illustrated in the supplementary results
Beads harbouring Anx and Ova were generated using sulfate fluospheres as basis. These
latex beads have a diameter of 1µm and proteins can be attached by passive adsorption.
Bead coating was performed at a bead concentration of 0.4% solids (2000 x 106 beads/266µl).
First, Ova [2 ng/106 beads] was diluted in DBPS in protein lowbind tubes and a sample
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was taken to monitor the input before coating. Beads were then added and the tubes
were rotated over night at 4 ◦C. Coated beads were then pelleted (5min, 13000 rpm, 4 ◦C)
and supernatant was kept to monitor how much of the input was bound to the beads.
The beads were then washed two more times before they were equally split into at least
two tubes. In one tube the beads were resolved in DPBS/1%mouse serum and rotated
over night at 4 ◦C for blocking and then used as control Ova-beads (OB). Meanwhile,
the second batch of Ova-coated beads was additionally coated with Anx by rotation over
night at 4 ◦C and washed three times. Again, samples from before and after coating were
kept to monitor coating efficiency. Finally, Ova-Anx-beads (OAB) were blocked over night
in DPBS/1%mouse serum. All coated beads were stored in DPBS/1%mouse serum at
4 ◦C.
The ratio between Ova and Anx was calculated with the number of molecules that should
attach to the beads assuming 100% efficiency. This means that OAB20 should harbour
20-fold more Anx molecules than Ova molecules. For OAB20 this would translate to
2 ngOva/106 beads and 29,7 ngAnx/106 beads.
3.5.2 Bead analysis
Beads were analysed after production to control successful coating but also regularly and
prior the every experiments to ensure stable binding and to monitor bead concentrations.
The bead production was initially controlled by western blot analysis as described in
3.3.1.5. However, this type of analysis was rather indirect and could be improved by
using FITC-labelled Ova which allowed analysis by fluorescence measurements. For FC
analysis the beads were diluted 1:100 and stained with α-Anx-APC. FC analysis provided
fluorescence intensity measures for Ova and Anx per bead and hence visualised protein
binding in general. Furthermore, it allowed to control stability of coating of the same bead
charge over time and also to compare coating between different bead charges. However,
quantification was not possible with this method. In order to quantify the amount of
Ova on the beads and also to analyse the input and output samples that were obtained
during the production, fluorescence was measured with a plate reader (GloMax, blue
filter (excitation 490 nm)). Using a standard curve of Ova-FITC, the amount of Ova-
FITC in the samples from the bead production and in a defined volume of bead solution
could be calculated. Combining this measurement with a bead count (as described in
the next paragraph), allows quantification of Ova-FITC per bead and accordingly coating
efficiency.
Bead quality and concentration was controlled prior to every experiment to ensure similar
bead numbers and consequently similar amounts of antigen for cell treatment. The bead
concentration was determined by counting the beads with TruCount tubes. These tubes
contain a pellet with a defined number of labelled beads. Solving this pellet in a defined
volume allows to calculate which sample volume was measured with FC and hence allows
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the correlation of the number of events measured by FC with a volume. In addition to the
counting prior to the assay, samples from the bead solutions prepared for cell treatment
were analysed post assay using the GloMax plate reader as described above to control
once more whether cells received similar amounts of Ova.
3.5.3 Nanoparticles
Nanoparticles (NP) were produced by Nanovex Biotechnologies S.L.. The nanoparticles
were made of poly(D,L-lactide-co-glycolide) (PLGA) with a L/G ratio of 50:50 and sur-
face modification with PEI. Ova was encapsulated in the NP while Anx was covalently
bound to PEI on the NP surface. ONP were characterised with a diameter of 222.4 nm,
a ζ-potential of 45.2mV and 0.5µgOva/mgNP. OANP were characterised with a dia-
meter of 247.7 nm, a ζ-potential of 19.9mV, 0.5µgOva/mgNP and 6.7µgAnx/mgNP
corresponding to a molecule ratio of 1:18 (Ova:Anx).
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4.1 Effects of soluble Anx on BMDC cytokine secretion
Annexins and in particular the annexin A1 core domain (Anx) was recently described
to have tolerogenic functions. 80,82 To further analyse the tolerogenic capacity of Anx on
BMDC, an in vitro suppression assay including apoptotic JE6.1 cells (aJ) as positive con-
trol was established (fig. 3A). As expected, cytokine suppression by aJ was observed in
all performed experiments. Representative examples of IL-12 (fig. 3B) and IL-6 (fig. 3C)
production show that aJ are able to keep the cytokine production at the baseline level of
untreated cells or even repress it to undetectable levels. For unstimulated BMDC, Anx
showed a suppressive activity comparable to aJ. Upon BMDC stimulation of the BMDC,
Anx was however not as potent as aJ. Nonetheless, Anx reduced IL-6 secretion signific-
(A)
(B) (C) (D)
Figure 3: Suppression BMDC cytokine production following incubation with apoptotic
cells or Anx. (A) BMDC were pre-treated with apoptotic JE6.1 cells (aJ) or Anx for 4 h and 8 h,
respectively, before they were stimulated with CpG. (B+C) BMDC were pre-treated as illustrated
in A and either left unstimulated or stimulated with CpG as indicated. Cytokine secretion was
analysed via ELISA using supernatants (SN) that were collected after 2 days. (D) Nine individual
experiments were summarised by normalising the IL-6 secretion to the IL-6 concentration in the
supernatants of cells only stimulated with CpG, without pre-treatment (reference condition). The
different Anx concentrations were analysed in separate experiments, however equally normalised
to their respective reference condition. Significance was calculated using paired t-test (* p<0.05,
** p<0.01, *** p<0.001).
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antly to approximately 60 % of the response seen in BMDC stimulated with CpG in the
absence of any pre-treatment (fig. 3D).
(A)
(B) (C) (D) (E)
Figure 4: Reduction of Ova-specific T cell stimulation following pre-incubation with
soluble Anx. (A) BMDC were pre-incubated for 7 h with Anx [1000 nM] before Ova [10µg/ml]
and, 1 h later, CpG were added. 2 days after treatment of the BMDC, CFSE-labelled OT-II T cells
were added and co-cultured for a total of 5 days before the T cells were harvested for FC analysis.
Supernatants for cytokine analysis were collected before T cells were added and on day 2 and day 5
of co-culture. (B) BMDC were treated as illustrated in A and supernatants collected before T cells
were added were used to measure IL-6 production from BMDC. (C) Following 2 days of co-culture
IL-2 production was analysed via ELISA. (D) Following 5 days of co-culture, IFN-γ production was
measured via ELISA. (E) T cells were harvested after 5 days of co-culture and proliferation of the
cells was determined by dilution of CFSE measured in FC. (B-E) show summaries of 5 independent
experiments each normalised to their respective control (response to Ova alone). Significance was
calculated using paired t-test (* p<0.05, ** p<0.01, *** p<0.001).
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4.2 Effects of soluble Anx and Anx-beads on antigen-specific
T cell responses
DC reside in the centre of the immune system and shape T cell responses. 9 Hence, the
Anx-mediated inhibition of inflammatory cytokine secretion from DC was hypothesised
to influence T cell responses as well. This hypothesis was investigated by expanding
the BMDC suppression assay with Ova as antigen and Ova-specific CD4+Tcells (OT-II
T cells).
4.2.1 Effects of soluble Anx on Ova-specific T cell responses
The OT-II system was used to evaluate whether BMDC pre-incubation with soluble Anx
as seen in figure 3 can influence T cell responses. Induction of OT-II T cell responses
requires presentation of the relevant antigen Ova by BMDC. For this reason, the BMDC
suppression assay was adjusted by adding recombinant Ova to the Anx-pretreated BMDC
1h prior to CpG stimulation (fig. 4A). Additionally, the assay was expanded by co-
culturing the pre-treated BMDC with CFSE-labelled OT-II T cells which were analysed
for cytokine production and proliferation.
The suppression of IL-6 illustrated in figure 3D was maintained in the presence of Ova
(fig. 4B). BMDC incubated with Ova and stimulated with CpG provoked a TH1-like
response in OT-II T cells represented by secretion of IL-2 and IFN-γ. Pre-incubation
with soluble Anx resulted in a strong reduction of the Ova-specific cytokine response
(fig. 4C, 4D) as well as in decreased proliferation (fig. 4E). These results indicate that the
tolerogenic function of Anx on BMDC is transferred to CD4+ Tcells.
4.2.2 Effects of Anx-beads on Ova-specific T cell responses
The regulatory functions of Anx might be valuable for the development of antigen-specific
therapies for autoimmune disease. Anx and Ova as antigen were coupled to polystyrene
beads in order to investigate the modulatory capacity of Anx in an antigen-specific con-
text. Details about the bead production and characterisation can be found in 3.5.1 and the
supplementary results. Briefly, beads are coated either with Ova alone as reference beads
(OB) or coated with Ova and Anx (OAB). All beads are coated with equal amounts of
Ova. If not indicated otherwise, Anx is coated in 20-fold excess. To analyse how the T cell
response is influenced by the beads, the suppression assay was performed similar to the
assays with soluble Anx and is schematically shown in figure 5A. A titration experiment
(n=3) with the beads was performed to determine an appropriate bead concentration
(fig. 5B-5D). 14 x 106 beads/ml triggered T cell responses that were detectable but not yet
in a plateau and thus this concentration was used for further experiments. Figure 5B-5D
shows that T cell responses could be inhibited by Anx-bead treatment of BMDC. This
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(A)
(B) (C) (D)
(E) (F) (G)
(H) (I) (J)
Figure 5: Attenuation of Ova-specific T cell stimulation by Ova-Anx-beads. (A) BMDC
were incubated with beads coated with Ova (OB) or OVA and Anx (OAB) before they were stimu-
lated with CpG. CFSE-labelled OT-II T cells were added and co-cultured for 5 days before the T cells
were harvested to analyse proliferation by FC. Supernatants for cytokines analysis were collected
before T cells were added (for IL-6) and on day 2 (for IL-2) and day 5 (for IFN-γ) of co-culture.
(B-D) summarise T cell responses to ascending bead concentrations of 3 independent experiments.
(E-J) illustrate the response to increasing amounts of Anx on the bead surface. (E-F) exemplifies
the raw data of one experiment including treatment with soluble Ova as positive control and the
responses in absence and presence of CpG stimulation. (H-J) show the summary of 7 independent
experiments, each individually normalised to the response to the control beads (OB). Significance
was calculated using paired t-test (* p<0.05, ** p<0.01, *** p<0.001).
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inhibitory effect is further depicted with a representative experiment using OAB with dif-
ferent Anx concentrations (fig. 5E-5G). Beads were coated with a 5-fold (OAB5), 10-fold
(OAB10) or 20-fold (OAB20) excess of Anx molecules in relation to Ova molecules. Fig-
ure 5E-5G illustrate that T cell responses were decreased in Anx-concentration-dependent
manner following co-culture with unstimulated and CpG-stimulated BMDC. This sup-
pressive effect compared to the response to beads with Ova alone was observed repro-
ducibly with a mean reduction of IL-2 secretion to 44.6% (fig. 5H), mean reduction of
IFN-γ secretion to 36.7% (fig. 5I) and mean reduction of proliferation to 57.9% (fig. 5J)
referring to the highest Anx concentration.
4.2.3 Specificity of the Anx-bead effects
(A)
(B)
Figure 6: Viability of BMDC and T cells is not im-
paired by beads. Cell viability was analysed using 7-AAD
staining to determine the percentage of living cells in the
whole cell population. (A) BMDC were pre-incubated with
Ova [10µg/ml] or beads [14 x 106/ml] prior to CpG stimula-
tion. 2 days after treatment, BMDC were harvested and
stained for CD11c and with 7-AAD to measure dead cells in
the CD11c+ compartment. (B) OT-II T cells were harves-
ted after 5 days of co-culture with pre-treated BMDC and
stained for CD4 and with 7-AAD to measure cell death in
the CD4+ compartment.
Several control experiments were
performed to validate that the
suppressive capacity of the Anx-
beads shown in figure 5 is me-
diated specifically by the pres-
ence of Anx on the bead sur-
face. First, it was examined
whether the beads show any tox-
icity and whether the beads show
any coating-related toxicity. Two
separate experiments showed that
the beads did not negatively influ-
ence BMDC viability irrespective
of the coating and the amount of
Anx on the bead surface (fig. 6A).
T cell viability could be affected
by the beads in two different ways:
either directly by potentially re-
maining beads in the culture that
have not been taken up by BMDC
or indirectly by effects mediated
through the bead-treated BMDC.
However, no bead-induced cell
death of T cells was detected
in two independent experiments
(fig. 6B). Viability was analysed
in experiments performed in parallel with suppression assays, suggesting that inhibited
T cell responses are not associated with increased cell death.
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(A) (B)
(C) (D)
(E) (F) (G)
Figure 7: Bead uptake, Ova processing and Ova presentation are not significantly
altered by Anx. (A+B) BMDC were incubated over night with beads [7.5 x 106/ml] and then
fixed and stained for microscopy. Representative images of the bead uptake by BMDC are shown
in A (yellow: beads; blue: hoechst, red: phalloidin) and the number of beads per cell quantified
over 17 images per condition is shown in B. (C) BMDC were pre-treated treated with fluorescent
beads [14 x 106/ml] and stimulated with CpG. 2 days later, BMDC were harvested, stained for
CD11c and their bead content was analysed by FC. Dots represent independent experiments. (D)
BMDC were incubated with soluble DQ-Ova [10µg/ml] or beads coated with DQ-Ova ± Anx for
3 h at 37◦C and 4◦C in parallel. Cells were then harvested and Ova degradation was evaluated
in FC. The background as determined by the signal measured at 4◦C was subtracted in each of
the 4 independent experiments. (E-G) BMDC were pre-treated as described for C and co-cultured
with CFSE-labelled OT-II T cells. For the indicated conditions, ISQ [0,005µM] was added at least
30min prior to the T cells. (E) After 2 days of co-culture, IL-2 production was analysed by ELISA.
(F) After 5 days of co-culture, IFN-γ production was measured by ELISA. (G) and proliferation of
harvested T cells was determined by FC (G). To allow direct comparison, results were normalised
to OB or OB + ISQ, respectively.
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Next, the uptake of the beads by BMDC was analysed by microscopy (fig. 7A, 7B) and
FC (fig. 7C). A yellow fluorescent variant of the polystyrene beads was used to visualise
phagocytosed beads. Due to the strong fluorescent signa of the yellow bead variant,
BMDC were treated over night with a reduced bead concentration before they were fixed
and stained for microscopy. Nuclei and beads were counted separately to calculate the
average number of beads per cell for each image. The summary of the images of one
experiment demonstrate similar bead content in cells incubated with either OB or OAB
(fig. 7B). Uptake was additionally analysed 2 days following bead treatment using the
assay setup described in figure 5A by measuring what proportion of CD11c+ cells were
positive for the fluorescent signal of the beads (fig. 7C). The number of beads taken up
per cell could not be estimated because the fluorescent signal of the beads was too high.
Nevertheless, the FC analysis supports the microscopy data in figure 7B demonstrating
that Anx-coating did not significantly alter uptake of the beads. These results exclude
that the reduced T cell responses described above caused by reduced availability of Ova
in the BMDC.
Anx might influence Ova processing and presentation, which could lead to less antigen
presentation and hence less T cell activity. An Ova protein variant which is coupled to
a processing sensitive dye (DQ-Ova) was utilised to evaluate processing in absence and
presence of Anx. DQ is quenched as long as the protein is intact but upon degradation
to smaller peptides the dye emits a fluorescent signal. Processing of DQ-Ova was neither
affected by the presence of 10-fold nor 20-fold excess of Anx on the bead surface (fig. 7D).
Presentation of Ova in the context of MHC II is difficult to measure directly due to the
lack of an antibody recognising the Ova-MHC II complex. ISQ was added to BMDC
prior to co-culture with OT-II T cells to indirectly assess whether T cell responses are
reduced due to differential antigen presentation or due to active modulation of the T cell
by the DC. The Ova peptide ISQ can be loaded into MHC II directly from the outside of
the cell and is independent of uptake and processing 216. The external loading with ISQ
can override any potential difference in antigen presentation on BMDC following bead
incubation. As illustrated in figure 7E-7G, T cell responses were similarly decreased by
OAB as compared to OB in absence and presence of ISQ. It should be noted that the
addition of ISQ did increase the T cell response which may account for differences in the
suppression. The stimulatory effects of ISQ are not represented in the graphs since the
response was normalised to the respective controls. Figure 7 demonstrates that T cells
are actively modulated by BMDC-intrinsic mechanisms induced by Anx-coated beads and
not by differences in antigen presentation.
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4.3 Effects of soluble Anx and Anx-beads on BMDC phenotype
Anx attenuates T cell responses in soluble and particulate form. This is however an indir-
ect effect on T cells mediated through the bead-treated BMDC. How the beads modulate
the BMDC phenotype is addressed in the following sections.
4.3.1 T cell suppression in the context of BMDC cytokine suppression
(A) (B)
(C) (D)
(E) (F)
Figure 8: Diminished T cell responses are inde-
pendent of BMDC cytokine suppression. (A-D)
BMDC were pre-incubated for 7 h with Anx [1000 nM] be-
fore Ova [10µg/ml] and 1 h later CpG were added. CFSE-
labelled OT-II T cells were added and co-cultured for 5 days
before the T cells were harvested to evaluate proliferation by
FC (D). Supernatants for cytokines analysis were collected
before T cells were added (A) and on day 2 (B) and day 5 of
co-culture (D). (A-D) show results from a single experiment
with triplicates for every condition. (E+F) BMDC were pre-
incubated with beads an then stimulated with CpG. 2 days
later supernatants were collected for ELISA. The data was
normalised to the control-beads (OB) and corresponds to
the data shown in figure 5H-5J.
Based on the initial finding that
soluble Anx can repress the se-
cretion of inflammatory cytokines
(fig. 3), it can be hypothesised
that the altered cytokine pro-
file modulates the T cell response.
However, in one experiment sol-
uble Anx failed to suppress IL-6
production in BMDC while the in-
hibitory effect on T cell level was
maintained (fig. 8A-8D). Further-
more, suppression of IL-6 or IL-12
secretion was never observed for
bead-bound Anx (fig. 8E, 8F) des-
pite the fact that T cell responses
were diminished in all correspond-
ing experiments (fig. 5). This in-
dicates, that in contrast to soluble
Anx, bead-bound Anx is not cap-
able of suppressing inflammatory
BMDC cytokines. Moreover, this
data shows that T cell inhibition
is independent of BMDC cytokine
suppression.
While decreased inflammatory cy-
tokine levels were negligible for
the modulation of T cell re-
sponses, anti-inflammatory cy-
tokines and mediators might be
involved. IL-10 and TGF-β se-
cretion by BMDC was not detect-
able 2 days following Anx or bead
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(A) (B)
(C) (D)
Figure 9: Expression of IL27, IDO, SOCS1 and SOCS3 was not modulated by Anx.
BMDC were incubated with soluble Anx or beads [14 x 106/ml] for 4 h before cells were harvested.
RNA was extracted from the cell lysates and analysed by qRT-PCR. Gene regulation was assessed
with the ∆∆CT method and using HMBS as reference gene. The lower Anx concentration (500 nM)
was analysed in separate experiments but equally normalised to their respective reference condition.
Experiments were performed in parallel to T cell suppression assays. Dots indicate independent
experiments and significance was calculated using paired t-test of log2 transformed data (* p<0.05,
** p<0.01, *** p<0.001).
treatment (data not shown). Additional anti-inflammatory cytokines and mediators were
analysed on mRNA level. While T cell suppression was observed in parallel, neither the
IL-27 subunit IL27p28 nor IDO was upregulated by Anx or Anx-beads (fig. 9A, 9B).
SOCS1 and SOCS3 are known negative regulators in DC. 76 Besides regulating the re-
sponse to exogenous cytokines they are also downstream targets of modulatory receptors
and thus a potential target of Anx. However, gene expression of SOCS1 and SOCS3 was
not altered by Anx in soluble or particulate form (fig. 9C, 9D).
The impact of soluble mediators was further examined by washing the BMDC prior to
co-culture with OT-II T cells. Exchanging the BMDC medium before the T cells are
added removes all soluble mediators secreted by BMDC in response to the beads. Figure
10 shows T cell responses to washed BMDC in a representative experiment. The lack
of soluble factors like pro-inflammatory cytokines produced by the BMDC in response to
CpG leads to a reduced T cell activity independent of any pre-treatment. Nevertheless, the
suppression of T cell cytokine secretion and proliferation by OAB is sustained indicating
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that Anx-mediated T cell suppression does not rely on the cytokine profile of BMDC.
(A)
(B)
(C)
Figure 10: Soluble mediators have a minor role for
T cell suppression by beads. BMDC were incubated
with beads before they were stimulated with CpG. 2 days
after the treatment, CFSE-labelled OT-II T cells were either
added directly (left panel) or BMDC were washed before
the OT-II T cells were added (right panel). (A) IL-2 pro-
duction was measured after 2 days of co-culture. (B) IFN-γ
production was measured after 5 days of co-culture. (C)
Proliferation was measured after 5 days of co-culture.
4.3.2 Effects on BMDC sur-
face marker expression
Anx-mediated T cell suppression
might be induced in cell-cell
contact-dependent manner, hence,
the surface expression of co-
stimulatory and co-inhibitory mo-
lecules on BMDC was ana-
lysed. Apoptotic cells attenu-
ated the activation-induced up-
regulation of MHC II and the
co-stimulatory molecules CD40
and CD86 (fig. 11A-11D). Neither
500 nM nor 1000 nM soluble Anx
was able to reproduce this ef-
fect (fig. 11E-11G). Interestingly,
apoptotic cells also impaired the
upregulation of the co-inhibitory
molecule PD-L1 (fig. 11D). A
slight decrease in PD-L1 expres-
sion was also seen in BMDC
pre-incubated with 1000 nM Anx
but the effect was not signific-
ant (fig. 11G). The surface ex-
pression of additional stimulatory
and inhibitory molecules, includ-
ing CD80, ICOSL, PD-L2 and
ILT3, was ex-amined on BMDC.
None of analysed markers were affected by soluble Anx (fig. 11H-11K).
The surface marker panel used in figure 11 was also analysed following pre-incubation
with beads (fig. 12). The bead material itself influences the expression of BMDC surface
markers. Both OB- and OAB-treated BMDC showed a more stimulatory phenotype than
non-bead-treated BMDC with increased MHC II, CD40, CD86 and CD80 levels (fig. 12A-
12C, 12G) and decreased PD-L1 and ILT3 levels (fig. 12D, 12F). Although a slight increase
in CD40, PD-L2 and ICOSL expression was detected in OAB-treated BMDC (fig. 12B,
12E, 12H), none of the analysed markers were altered significantly in OAB-treated com-
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(A) (B) (C) (D)
(E) (F) (G)
(H) (I) (J) (K)
Figure 11: Alterations in BMDC surface marker expression by apoptotic cells and
soluble Anx. BMDC were pre-incubated with Anx or apoptotic JE6.1 cells (aJ) and stimulated
with CpG. On the following day (E-K) or after 2 days (A-D), BMDC were harvested and stained
for FC analysis. Surface marker expression is shown for pre-gated CD11c+ BMDC with each dot
representing an independent experiment.
pared to OB-treated BMDC.
4.3.3 Effects on ROS production
Reactive oxygen species (ROS) were long considered to be harmful. However, in the
last decade ROS like H2O2 were recognised as important modulators of diverse signalling
pathways. Furthermore, ROS are implicated in T cell hyporesponsiveness. 217,218 Whether
Anx can cause ROS production was investigated using DCFDA, a molecule that becomes
fluorescent upon oxidation. Soluble Anx induced ROS production in BMDC peaking
2 h after treatment (fig. 13A). In In contrast to an oxidative burst as seen after PMA
treatment, Anx provoked a low ROS signal (mean 25.8% specifc MFI increase) which is
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(A) (B) (C) (D)
(E) (F) (G) (H)
Figure 12: Alterations in BMDC surface marker expression by beads. BMDC were pre-
incubated with beads before and stimulated with CpG. On the following day, BMDC were harvested
and stained for FC analysis. T cell suppression was analysed in parallel. Surface marker expression
is shown for pre-gated CD11c+ BMDC with each dot representing an independent experiment.
(A) (B) (C)
Figure 13: ROS production is increased by soluble Anx and Anx-beads. BMDC were
treated with the listed substances for 2 h (or as indicated) and incubated with DCFDA in the last
30min of the treatment. ROS production is shown relative to untreated cells or a reference condi-
tion. (A) Kinetic of the Anx-induced ROS production measured in triplicates. (B) Summary of 4
independent experiments including pre-treatment with the ROS scavenger Trolox 10min prior to the
addition of Anx. (C) BMDC were treated with beads [14 x 10 6/ml] and ROS production normalised
to control-beads (OB). Dots indicate independent experiments. Significance was calculated using
paired t-test (* p<0.05, ** p<0.01, *** p<0.001).
suitable to modulate signalling without killing the cell 219. The Anx-induced ROS was
specifically blocked by the ROS scavanger Trolox (fig. 13B). Beads did also induce ROS
production and despite the increased background ROS in OB-treated cells, the signal was
further elevated with OAB (fig. 13C). This data shows that both soluble and bead-bound
Anx induce ROS generation which might have modulatory effects on BMDC and T cells.
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4.4 Effects of soluble Anx and Anx-beads on T cell phenotype
Soluble Anx and Anx-beads modulate Ova-specific T cell responses as demonstrated in the
previous figures. The following section addresses the T cell phenotype and the potential
mode of tolerance induced by Anx-treated BMDC.
4.4.1 Effects on T cell cytokine production
The T cell cytokine profile provides information about the T cell subtype. The presenta-
tion of Ova by BMDC (unstimulated as well as CpG-stimulated) results in differentiation
of OT-II T cells into TH1 cells, characterised by IFN-γ secretion. Alternative differen-
tiation or conversion into TH2 cell was not observed, since IL-4 was neither detectable
in untreated nor bead-treated conditions (data not shown). Reduced production of IL-
2, IFN-γ (fig. 5) and TNF-α (fig. 14A), a pro-inflammatory cytokine involved in the
pathogenesis of asthma and allergy, indicates that Anx-beads attenuate pro-inflammatory
cytokine responses from Tcells. Whether T cells additionally gained anti-inflammatory
functions was investigated by measuring secretion of IL-10 and TGF-β, which are associ-
(A) (B) (C)
(D) (E)
Figure 14: Global T cell cytokine suppression by Anx-beads. (A-C) BMDC were pre-
incubated with Ova or beads prior to stimulated with CpG. CFSE-labelled OT-II T cells were
co-cultured with treated BMDC for 5 days and cytokine production was measured by ELISA.
(A) TNF-α production was evaluated in triplicates.(B+C) Cytokine production was normalised to
the non-pre-treated but CpG-stimulated condition and summarised with each dot representing an
independent experiment. (D+E) BMDC were pre-incubated with Ova or beads prior to stimulated
with CpG. Activated OT-II T cells were co-cultured with treated BMC and cytokine production
was measured after 2 days (D) or 5 days (E) by ELISA. D + E show results from one experiment,
performed with triplicates for each condition.
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ated with regulatory T cell subtypes (fig. 14B, 14C). IL-10 and TGF-β levels were low in
OT-II T cells following co-culture with BMDC and pre-treatment with Anx-beads further
diminished the secretion of these cytokines (fig. 14B, 14C). These results suggest a global
suppression of cytokine production including both pro- and anti-inflammatory cytokines.
Furthermore, cytokine secretion was also found to be inhibited in preliminary experiments
with pre-activated T cells (fig. 14). Co-culturing bead-treated BMDC with OT-II T cells
that were pre-activated with αCD3/αCD28 resulted in reduced IL-2 and IFN-γ levels as
exemplified in figure 14D and 14E.
4.4.2 Effects on T cell surface marker expression
Although anti-inflammatory cytokines like IL-10 or TGF-β are common mediators of tol-
erance, regulatory T cell subsets utilise several effector mechanisms in addition to these
cytokines. For instance, FoxP3+ Treg are described to rely on contact-dependent mech-
anisms rather than cytokine secretion. 107,108 Hence, tolerogenic properties including the
expression of FoxP3 and co-inhibitory molecules were investigated. Activation of OT-II
T cells by BMDC treated with soluble Ova or beads decreased the proportion of FoxP3+
cells and Anx-beads were neither able to initiate FoxP3 expression nor to prevent the
(A) (B)
(C) (D) (E)
Figure 15: Anti-inflammatory marker are scarcely influenced by Anx-beads. BMDC
were pre-incubated with Ova or beads prior to stimulated with CpG. CFSE-labelled OT-II T cells
were co-cultured with treated BMDC. (A) Following 7 days of co-culture, T cells were harvested and
analysed for FoxP3 expression by FC. The bars show mean and SD of 2 independent experiments.
(B-E) Following 5 days of c-culture, T cells were harvested, stained for the indicated surface molecules
and analysed by FC. MFIs of each experiment were normalised to the MFI of the respective reference
condition (OB). Significance was calculated using paired t-test (* p<0.05, ** p<0.01, *** p<0.001).
47
4 Results
activation-related reduction in FoxP3 expression (fig. 15A).
A variety of co-inhibitory receptors affect tolerance induction and maintenance. PD-1
and CTLA-4 are crucial for peripheral tolerance while Tim-3 and Lag-3 are often de-
scribed to cooperate with other molecules to support tolerance. Thus, these receptors
might also contribute to Anx-bead mediated effects on T cells. However, the surface
expression of PD-1, CTLA-4 and Lag-3 was not modulated in OT-II T cells following
co-culture with Anx-bead-treated BMDC (fig. 15B-15D). Tim-3 was significantly modu-
lated by Anx-beads (fig. 15E). The average increase in the MFI of Tim-3 in the CD4+
T cell compartment was 13.3%. It should however be noted that only a small subset of
maximally 20% of OT-II T cells were Tim-3 positive.
4.4.3 Evaluation of anergy-related characteristics
Tcell tolerance is often described in three categories: T cell deletion, T cell anergy and
Treg cells. Anergy is a state of unresponsiveness, mainly described by attenuated prolifer-
(A) (B)
(C) (D) (E)
Figure 16: An anergic phenotype is only partly observed in Anx-bead treated T cells.
BMDC were pre-incubated with Ova or beads prior to stimulated with CpG. CFSE-labelled OT-
II T cells were co-cultured with treated BMDC. (A) Following 5 days of co-culture, T cells were
harvested, stained for the indicated surface molecules and analysed by FC. Each experiment was
normalised to the respective reference (OB). (B-E) If not stated otherwise, T cells were harvested
after 4 h of co-culture to analyse gene expression via qRT-PCR using HPRT as reference gene. (B)
IL-2 expression was analysed after 4h (left) and 24h (right) and is shown relative to the expression
in the OB condition. (C-E) Expression of the indicated genes is illustrated relative to the expression
of T cells co-cultured with non-pre-treated but CpG-stimulated BMDC. Dots indicate independent
experiments and significance was calculated using paired t-test of log2 transformed data (* p<0.05,
** p<0.01, *** p<0.001).
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ation and cytokine production. 87 These properties were observed in OT-II T cells following
co-culture with Anx-treated BMDC (fig. 4, fig. 5). In order to test the hypothesis that
Anx-beads induce T cell anergy, additional markers associated with an anergic phenotype
were analysed (fig. 16).
Some publications describe a anergic T cell population in vivo which is double-positive for
CD73 and FR4 surface marker expression. 105,220 Anx-bead treatment did not result in a
significant increase of the CD73+, FR4+ subpopulation in OT-II T cells in vitro (fig. 16A).
A hallmark of anergy is impaired IL-2 transcription. 87,221 In addition to reduced IL2 se-
cretion demonstrated in figure 5, co-culture of T cells with Anx-bead treated BMDC led
to significantly decreased IL-2 mRNA expression after 24 h (fig. 16B). The same trend
was observed after 4 h. IL-2 transcription requires both TCR and CD28 signalling. The
lack of co-stimulation via CD28 results in an alternative transcription programme includ-
ing Egr2 expression which in turn enhances the expression Cblb and GRAIL. All three
mentioned factors are implicated in T cell anergy 87,221,222 and were thus analysed in OT-II
T cells 4 h after co-culture with bead-treated BMDC (fig. 16C-16E). The increase in ex-
pression of Egr2, Cblb and GRAIL following Anx-bead treatment is not significant and
quantitatively not comparable with gene expression profiles of anergic T cells found in lit-
erature 98,99,101,102,223,224. Similarly, soluble Anx mediated a decrease in IL-2 transcription
while the other anergy-associated genes tested were unaffected (fig. S6).
49
4 Results
4.5 In vivo effects of Anx-beads
Anx-beads were able to suppress T cell responses in vitro and it was investigated whether
this effect can be reproduced in vivo.
Mice were first treated with the control-beads (OB) to estimate an appropriate bead
concentration for further in vivo experiments (fig. 17A). 6 days after treatment, the
(A)
(B) (C)
(D) (E)
Figure 17: T cell proliferation in vivo is induced by control-beads in a concentration
dependent manner. 1.5 x 106 CFSE-labelled OT-II T cells were transferred into wt mice one day
prior to i.v. injection of PBS (mock), the indicated amounts of beads or 500µgOva/50µgαCD40. 6
days after treatment mice were sacrificed to analyse T cell responses in the spleen. Mean and SD of
2 mice are shown for the bead treatments. (A-D) Splenocytes were isolated, stained and analysed by
FC. (E) Splenocytes were restimulated with the relevant Ova-peptide ISQ or stimulatory antibodies
for 4 days before supernatants (SN) were analysed by ELISA. Graphs show baseline-subtracted
cytokine secretion
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transferred OT-II T cell comprised 0.59 - 0.88% of the CD4+ Tcells in the spleens of
bead-treated mice, showing that OB caused an active response to Ova compared to the
mock treatment (PBS) with only 0.16% OT-II T cells (fig. 17B). 25 x 106 beads per mouse
were sufficient to induce proliferation in 64.1% of the transferred T cells in vivo whereas
100 x 106 beads per mouse induced proliferation in almost all (89.8%) transferred T cells
(fig. 17C). In line with the proliferation, the expression of the activation marker CD44
(A) (B)
(C) (D)
Figure 18: Co-stimulation with αCD40 was not sufficient to induce antigen-specific
cytokine responses in vivo. 2 x 106 CFSE-labelled OT-II T cells were transferred into wt mice
one day prior to i.v. injection of with the PBS (mock) or 50 x 106 OB with the indicated amounts of
αCD40. 5 days after treatment mice were sacrificed to analyse T cell responses in the spleen. Mean
and SD of 2 mice are shown for all treatments except the mock treatment. (A-B) Splenocytes were
isolated, stained and analysed by FC. (D) Splenocytes were restimulated with mock-peptide (SIY),
Ova-peptides (ISQ, SIINF) or stimulatiory antibodies (α-CD3/α-CD28) for 2 days (IL-2) or 4 days
(IFN-γ) before supernatants were analysed by ELISA. Graphs show baseline-subtracted cytokine
secretion
was enhanced with increasing bead concentrations (fig. 17D). This T cell activation was
however not reflected in IFN-γ secretion upon ex vivo restimulation. The antigen-specific
response to the Ova peptide ISQ in T cells from bead-treated mice was comparable to the
baseline IFN-γ secretion from Tcells from mock-treated mice. Only the positive control
treatment with Ova/αCD40 resulted in increased Ova-specific IFN-γ secretion (fig. 17E).
These results indicate that the control-beads alone may not be sufficient to provoke a
complete T cell responses in vivo including both proliferation and cytokine production.
In order to complement the T cell activation in vivo, αCD40 was co-administered with
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the beads. However, αCD40 had no additive effect on the T cell response induced by
OB (fig. 18). Contrary to the expectations, the response was decreased in the presence
of αCD40 and IFN-γ secretion following ex vivo restimulation remained below the levels
of the mock treated mouse). Antigen-specific secretion of IL-2 above the mock level was
detected from mice treated with OB alone (fig. 18C).
Despite the insufficient cytokine responses seen in figure 17 and 18, Anx-beads were used
in vivo to compare the effects of OB and OAB (fig. 19). Similar proliferation and cy-
tokine secretion were observed in response to OB and OAB (fig. 19C-19E). The absolute
number of OT-II T cells per spleen was reduced from an average of 3.2 x 104 cells after
OB treatment to an average of 1.9 x 104 cells after OAB treatment (fig. 19B).
The effect of OB and OAB on T cells in vivo was further investigated in the presence of co-
stimulation by polyI:C (fig. 19F-19J). The absolute number and the percentage of OT-II
T cells in the spleen 6 days after treatment was decreased in mice treated with OAB com-
pared to mice treated with OB (fig. 19F, 19G) while proliferation was similar (fig. 19H).
Deviating from the previous experiment, IL-2 production was higher in the OAB-treated
mice compared to the OB-treated mice. However, the high variance within the groups
hinders data interpretation (fig. 19I). The co-administration of polyI:C raised the IFN-γ
secretion from CD4+ T cells of OB-treated mice above the level of mock mice (fig. 19J).
The average of IFN-γ secretion in response to ISQ was 154 pg/ml in OB-treated mice and
43.7 pg/ml in OAB-treated mice. Although no clear Anx-mediated effects were observed,
this experiment showed that bead treatment in the presence of polyI:C can provoke po-
tent T cell responses. The secretion of IL-2 and IFN-γ in response to the MHC I-peptide
SIINFEKL demonstrates that Ova-specific CD8+ Tcells from the endogenous T cell pop-
ulation of the mice were expanded (fig. 19I, 19J).
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(A) (B) (C)
(D) (E)
(F) (G) (H)
(I) (J)
Figure 19: Anx-beads induce similar responses as control-beads in vivo. 1.5 x 106 CFSE-
labelled OT-II T cells were transferred into wt mice one day prior to i.v. injection of with PBS
(mock), 50 x 106 beads, 250µgOva/50µgαCD40 (A-E) or 100µgOva/50µgαCD40 (F-J). If indic-
ated, treatment was supplemented with 25µg polyI:C. 6 days after treatment mice were sacrificed
to analyse T cell responses in the spleen. Mean and SD of 3 mice are shown for the bead treat-
ments. (A-C; F-H) Splenocytes were isolated, stained and analysed by FC. TruCount tubes were
used to calculate the number of transferred cells. (D-E; I-J) Splenocytes were restimulated with
Ova-peptides (ISQ, SIINF) or stimulatiory antibodies (α-CD3/α-CD28) over night for IL-2 analysis
or for 4 days for IFN-γ analysis. Graphs show baseline-subtracted cytokine secretion
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4.6 Effects of Anx-nanoparticle on BMDC and T cells
Polystyrene beads are a tool often used in preliminary studies for a proof of concept
since they are commercially available and protein coating to such beads is easier com-
pared to protein coating to particles of other material. Nevertheless, polystyrene beads
are not applicable for therapeutic use in patients. Thus, the suppressive antigen delivery
mediated by Anx needs to be translated to particles of appropriate material. PLGA is
a FDA-approved polymer widely used as nanoparticulate carrier. In collaboration with
(A) (B) (C) (D)
(E) (F) (G) (H)
(I) (J) (K) (L)
.
Figure 20: Nanoparticle show only minor effects on BMDC phenotype. BMDC were
pre-incubated with NP [1µg/ml] and stimulated with CpG. (A) Supernatants were collected 1-2
days after treatment to analyse IL-6 secretion by ELISA. (B-H) 1 day after treatment, BMDC were
harvested and stained for FC analysis. Surface marker expression is shown for pre-gated CD11c+
BMDC. (A-H) show results normalised to the non-pre-treated but CpG-stimulated condition for
each experiment. (I-L) RNA lysates collected 4 h after treatment were analysed by qRT-PCR.
Gene regulation was assessed using HMBS as reference gene and the ∆∆CT method. Results
were normalised to the non-pre-treated but CpG-stimulated condition. Dots indicate independent
experiments and significance was calculated using paired t-test of log2 transformed data (* p<0.05,
** p<0.01, *** p<0.001)
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Nanovex Biotechnologies, PLGA-NP were generated which encapsulate Ova (ONP) and
in addition have Anx covalently attached to their surface (OANP).
First, the effects of the NP on BMDC were investigated in suppression assays analogous
to those used with soluble Anx or beads (fig. 3A). In high concentrations, NP them-
selves suppressed IL-6 production independent of the NP loading (data not shown). This
phenomena was also observed with polystyrene beads (fig. S5A-S5B). The working con-
centrations used for beads and NP were adjusted to cause minimal unspecific BMDC
cytokine suppression. IL-6 secretion was comparable after pre-treatment with ONP or
OANP (fig. 20A). Furthermore, Anx-NP had no anti-inflammatory effect on BMDC
at the level of surface molecule expression (fig. 20B-20H). Irrespective of Anx presence,
CD40 and PD-L2 expression was slightly decreased (fig. 20C, 20G) whereas PD-L1 and
ILT3 expression was slightly increased (fig. 20F, 20H) suggesting different basic properties
of polystyrene and PLGA particles. At the level of gene transcription, NP did not signi-
ficatnly modulate IDO, IL-27 and SOCS3. SOCS1 was significantly regulated by OANP
but the relevance of this effect is questionable.
Second, the effects of NP on T cell responses were analysed. Titrations, illustrated by a
representative experiment in figure 21A-21D, demonstrated a NP concentration-dependent
T cell activation. The suppressive activity of Anx-beads on IL-2, IFN-γ and proliferation,
was not reproduced with Anx-NP (fig. 21B-21G). Furthermore, no increase in the mRNA
expression of anergy-related genes with OANP was detected (fig. 21H-21J). Interestingly,
the control-NP themselves upregulated the expression of Egr2, Cblb and GRAIL to about
1.5-fold but the presence of Anx seemed to counteract this effect.
In summary, the generated Anx-NP have no inhibitory function and a refinement of the
NP properties may be necessary to promote the desired Anx-mediated suppression.
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(A) (B)
(C) (D)
(E) (F) (G)
(H) (I) (J)
Figure 21: Attenuation of Ova-specific T cell stimulation was not reproduced by Anx-
NP. BMDC were pre-incubated with Ova or beads prior to stimulated with CpG. CFSE-labelled
OT-II T cells were co-cultured with treated BMDC. (A) IL-6 production was measured before T
cells were added.(B+E) IL-2 production was measured after 2 days of co-culture. (C+F) IFN-γ
production was measured after 5 days of co-culture. (D+G) Proliferation was evaluated by CFSE
dilution measured after 5 days of co-culture. (A-D) show a representative titration experiment
performed with triplicates for each condition. (E-F) show a summary of experiments performed
with 1µg NP/ml normalised to the control-NP (ONP). (H-J) T cells were harvested after 4 h of co-
culture with BMDC treated with 1µg NP/ml. Gene expression was analysed via qRT-PCR using
HPRT as reference gene. Expression of the indicated genes is illustrated relative to the expression
of T cells co-cultured with non-pre-treated but CpG-stimulated BMDC.Dots indicate independent
experiments.
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Apoptotic cells are essential for the maintenance of peripheral tolerance and to prevent
autoimmunity. 67,225,226 The uptake of apoptotic cells induces a tolerogenic phenotype in
phagocytes and thus antigens associated with apoptotic cells (mainly self-antigens) are
presented in a tolerogenic context. 65 Due to this regulatory function, apoptotic cells were
recognised as a vehicle to promote antigen-specific immunosuppression. The reinfusion of
endogenous cells that were fixed with antigen and rendered apoptotic ex vivo was shown
to ameliorate autoimmune disease in mice and is also investigated in patients. 145,146,149,227
The adoptive transfer of cells in a clinical setting is however challenging and a syn-
thetic antigen delivery system that mimicks the properties of apoptotic cells would be
favourable. Although the mechanisms underlying apoptotic cell-mediated tolerance are
incompletely understood, several suppressive mediators of apoptotic cells were charac-
terised 79,225,226 and could be utilised to engineer apoptotic cell-like vehicles. Our group
identified the annexin protein family as such a mediator and demonstrated that the evol-
utionary conserved core domain of annexin contributes to the anti-inflammatory effects of
apoptotic cells. 80,82 This study examined Anx as a tool to induce antigen-specific immuno-
suppression. Particles harbouring Anx and the model-antigen Ova were generated using
either polystyrene or PLGA as basic material. The modulatory effects on Ova-specific
T cell responses of these Anx-particles as well as of soluble Anx were investigated on DC
and CD4+ Tcell level.
5.1 Anx affecting DC phenotype and DC response to TLR chal-
lenge
AnxA1 was previously described to modulate APC responses to TLR challenge. 80,82,200,228
In line with these reports, figure 3 demonstrated that pre-incubation with soluble Anx
inhibits IL-6 and IL-12 secretion from BMDC.
The suppression of inflammatory cytokines is an indirect readout of the inhibitory activ-
ity of Anx including pre-incubation and CpG stimulation. The steady-state cytokine
secretion of BMDC is low and TLR stimulation raises the activity of BMDC to facilitate
cytokine detection. In spite of apoptotic cells being potent immunosuppressors in steady-
state and inflammatory conditions 72,73, it was shown that the inhibition of TLR responses
was most pronounced when DC were co-cultured with apoptotic cells 3 h prior to TLR
stimulation 229. Furthermore our group observed that cytokine repression by AnxA1 re-
quired pre-incubation. 230 Accordingly, in all experiments presented in this study, BMDC
were incubated with Anx or aJ prior to CpG stimulation.
Soluble Anx interferes with TLR induced cytokine secretion but the effector mechanism
leading to the suppression of pro-inflammatory cytokines are elusive. SOCS proteins are
57
5 Discussion
well-known regulators of cytokine signalling and target the downstream-signalling of dif-
ferent TLRs 231,232. The inhibition or lack of SOCS1 or SOCS3 was shown to result in
enhanced cytokine responses 231,233. Alterations in SOCS activity is thus a candidate ef-
fector mechanism of Anx. However, neither soluble nor particulate Anx modulated the
expression of SOCS1 or SOCS3 in BMDC analysed 4 h after treatment (fig. 9C, 9D).
Similar results were obtained from BMDC incubated with Anx for 8 h and 24 h (data not
shown). Nevertheless, it can not be excluded that a regulation of these genes occurred
at time points not covered in this analysis. Interestingly, SOCS3 is reported to be up-
regulated by apoptotic cells and by an N-terminal peptide of AnxA1 (Ac2-26) leading
to phosphorylation of STAT3 228. Full-length AnxA1 also induced SOCS3 expression in
human monocytes-derived DC, but this upregulation was shown to be dispensable for
cytokine suppression. 230 The discrepancy between the present study and the indicated
literature on SOCS3 regulation can be explained by the use of different cell types from
different species and by the use of different annexin proteins/peptides. Pupjalis et al.
described the effect on SOCS3 specifically for the N-terminus of AnxA1 228 and the work
of Jahndel et al. used the full-length AnxA1 including this N-terminus 230 whereas the
present study utilised the core domain of AnxA1 excluding effects of the N-terminus.
Nevertheless, STAT3 phosphorylation in response to Anx should be examined to confirm
that the core domain does not influence SOCS3 activity.
NF-κB is a master regulator of gene transcription and is amongst others associated with
cell activation and pro-inflammatory responses e.g. to TLR stimulation. Many regula-
tory pathways result in inhibition of NF-κB. AnxA1 was shown to reduce phsphorylation
of the NF-κB subunit p65 and to decrease binding of NF-κB to DNA 80,230. This effect
was not validated for the core domain, yet, and the signalling events upstream of NF-κB
regulation need to be further analysed. Apoptotic cells mediate NF-κB inhibition by a
variety of pathways including SOCS, and PPARγ signalling 73,228,234,235. While SOCS1
and SOCS3 could not be associated with Anx in the present study, PPARγ is an inter-
esting candidate target for Anx and should be investigated. Another candidate target
for Anx is Nr4a1 which is a nuclear receptor described to inhibit NF-κB activity and
IL-12 induction. Nr4a1 interacts with TRAF6 and binds to p65 preventing NF-κB-DNA
binding 236.
A second comprehensive pathway involved in signal transduction of many receptors is
the Ca2+-calcineurin-NFAT axis. PRRs like TLR4 or the C-type lectin dectin-1 activate
calcineurin which modulates pro- and anti-inflammatory cytokine responses. 237 Interest-
ingly, calcineurin inhibition, e.g. by tacrolimus, was associated with reduced 238–240 as
well as with increased cytokine responses 241,242. In addition to the impact on cytokine
secretion, Ca2+ signalling plays a role in DC development and maturation. GM-CSF is
a NFAT target and calcineurin impairment was associated with an anti-inflammatory or
immature DC phenotype. 243–245 Hence, calcineurin and NFAT activity should be analysed
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to further elucidate the mode of action of Anx.
Tolerance induction involves the combination of several signals that determine the type of
immune response. Reduced levels of pro-inflammatory cytokines can be one of these sig-
nals but are not sufficient to induce immunosuppression.Thus, it was investigated whether
Anx specifically antagonises TLR signalling or whether it has a broader effect on the
BMDC phenotype.
Figure 3B and 3C exemplify that Anx attenuated IL-6 and IL-12 secretion in the absence
of TLR-stimulation with CpG which demonstrates that Anx activity is not restricted to
TLR signalling. We hypothesised that Anx causes a tolerogenic phenotype in BMDC.
Tolerogenic DC are not strictly defined and the characteristics of DC that exert immuno-
suppressive functions vary between different studies. Nonetheless, tolerogenic DC are
commonly described to express anti-inflammatory mediators and to show an immature
phenotype. 43,66
Anx did not enhance IL-10 and TGF-β secretion or alter IDO expression (data not shown,
fig. 9B) which are the most prominently described soluble anti-inflammatory mediators.
Moreover, the inhibitory surface molecules PD-L1, PD-L2 and ILT3 were not upregulated
by Anx, either (fig. 11D, 11G-11I, fig. 12D-12F). PD-L1 was upregulated by AnxA1 in hu-
man PBMC 80,230 whereas Linke et al. showed no regulation of PD-L1 by AnxA1, AnxA5
or AnxA13 in mouse BMDC 82. The latter is in line with the results in figure 11D,11G and
12D. Interestingly, apoptotic cells did not upregulate PD-L1 but prevented stimulation-
induced upregulation of PD-L1 in this system (fig. 11D). An immature phenotype is
characterised by low expression of co-stimulatory molecules. In accordance with the lit-
erature 77–79,246,247, figure 11A-11D showed that MHC II, CD40, CD80 and CD86 levels
remained low following TLR stimulation when BMDC were pre-treated with apoptotic
cells. However, Anx pre-treatment did not significantly modulate the expression of these
markers in the same experimental setting (fig. 11A-11F, 11K, fig. 12A-12C, 12H). Con-
trary to these results, Linke et al. reported downregulation of CD80 and CD86 by AnxA1,
AnxA5 and AnxA13 82. This discrepancy may be due to the use of different mouse strains
and annexin protein preparations.
In the present study, Anx failed to preserve an immature phenotype in BMDC following
TLR challenge. Nonetheless, Anx might still induce tolerogenic DC with an semi-mature
phenotype. A number of studies reported immunosuppressive activity by DC which ex-
press enhanced levels of co-stimulatory molecules 45,48,50,248,249. For instance, Menges et
al. reported that DC treated with the pro-inflammatory cytokine TNF-α have a mature
phenotype but generate only low amounts of cytokines. In spite of the maturation, these
DC cause T cell tolerance and ameliorate EAE. 249 Moreover, it was appreciated that a
certain degree of DC maturation is beneficial to induce T cell tolerance. Immature DC
efficiently endocytose antigens whereas antigen processing and presentation is more ef-
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ficient in mature DC. Thus, increased MHC II levels can support the interaction of DC
and T cells in an anti-inflammatory context. Further examples are CCR7 which allows
migration of the DC to reach the relevant T cells and CD40 which promotes DC survival
in a positive feedback loop. 45,118,250
This study is the first to show that Anx provokes ROS production in BMDC (fig. 13). In
contrast to the PMA-induced oxidative burst, the ROS signal in response to Anx is low
suggesting a role of ROS as signalling mediator 219.
ROS, especially H2O2, can modulate a variety of signalling pathways and cellular pro-
cesses like pagosomal acidification which is a requisite for the cross-presentation of anti-
gens 251. H2O2 is relatively stable and thus it can act over short distances between cells
and can even cross cell membranes to act in paracrine and autocrine manner. Further-
more, it is an ubiquitous signalling messenger by selectively oxidising proteins. 217,218,252
Cysteins are the main targets of H2O2 but only specific cysteins in coordination with
other adjacent amino acid can react with H2O2 in a process called sulfenylation. Similar
to phosphorylation, sulfenylation leads to post-translational modifications which influence
protein conformation and activity. 252–254 As such, ROS affects transcription factors like
NF-κB and AP-1. 255 The regulation of NF-κB by Anx might be mediated by ROS similar
to the reduced NF-κB activity in neutrophils treated with H2O2 observed by Zmijewski
et al. 256.
The impact of ROS for anti-inflammatory immune responses was emphasised in context
with NADPH oxidase 2 (NOX2) which is the major cellular source of H2O2 and signalling
ROS in immune cells. 257 Impaired function of NOX2 was associated with exacerbated
autoimmune disease in rodent models of arthritis and MS. 258–261 In addition, NOX2-
dependent ROS generated by myeloid-derived suppressor cells (MDSC) acts as feedback
to maintain the MDSC in an undifferentiated state and also supports the immunosup-
pressive properties of MDSC. 262,263 Preliminary experiments showed that both soluble and
particulate Anx generate ROS via NOX2 (personal communication Kevin Bode, DKFZ
Heidelberg) and we hypothesise that the tolerogenic effects of Anx are at least partly
mediated by ROS.
5.2 Comparison of soluble and particulate Anx
This study examined the effects of Anx in soluble and particulate form. The type of
Anx presentation had minor influence on ROS production (fig. 13) and surface molecule
expression (fig. 11, fig. 12) while suppression of IL-6 and IL-12 was only observed with
soluble Anx (fig. 3) and not with Anx-particles (fig. 8E, 8F, fig. 20A).
Particulate structures are generally thought to be pro-inflammatory and inflammasome
activation was described e.g. for bacteria and synthetic particle preparations 264–266. IL-1β
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which is produced in response to inflammasome activation was not detectable in super-
natants of BMDC treated with OB or OAB (data not shown). The polystyrene bead
preparations did however increase the expression of co-stimulatory surface markers and
decreased the expression of co-inhibitory molecules independent of Anx (fig. 12). It can
be speculated that these pro-inflammatory effects of the bead material override the anti-
inflammatory effects of Anx on BMDC cytokine production. However, the control-beads
were not observed to enhance IL-6 or IL-12 secretion in the presence and absence of CpG
stimulation (fig. S5C-S5D) and initial bead titration experiments showed a reduction in
pro-inflammatory cytokine responses with increasing bead-concentration independent of
Anx (fig. S5A-S5B). Moreover, both soluble Anx and Anx-beads were able to suppress
Ova-specific T cell responses (fig. 4, fig. 5) demonstrating an anti-inflammatory function
of bead-bound Anx. Thus, it is unlikely that intrinsic inflammatory bead properties ac-
count for the lack of cytokine suppression by Anx-beads.
An alternative explanation for the divergent effect of soluble Anx and Anx-beads on
BMDC cytokine regulation may be an altered interaction with potential receptors and
hence different downstream signalling. The geometry of a ligand can modulate signal
intensity and can even lead to different signalling outcomes. For instance, phagocytic
receptors work cooperatively to achieve phagocytosis and to efficiently induce signalling.
NFAT activation was found to be a shared endpoint in the signalling of diverse phagocytic
receptors. 267 Furthermore, single receptors can signal distinctively depending on ligand
properties like affinity and duration of ligand-receptors interaction. The immunoreceptor
tyrosine-based activation motif (ITAM) domain, e.g. present in C-type lectin receptors, is
sensitive to the nature of the ligand. High avidity ligands which are often patriculate lead
to complete phosphorylation of the domain and recruitment of Syk resulting in an inflam-
matory response. On the contrary, low avidity ligands can lead to hypophosphorylation
of the ITAM domain and recruitment of phosphatases via SH2 resulting in inhibitory
signalling. 268–272 Beyond the differences of soluble and particulate ligands, the distinct
form of particulation can influence the response. PS was complexed in different particles
to promote anti-inflammatory responses. Interestingly, the comparison of equally loaded
liposomes, cylindrical PLGA-particles and rod-shaped PLGA-particles revealed superior
function of PS in rod-shaped particles. 179
The receptor or receptors of the annexin core domain have not been identified, yet. Non-
etheless, it can be speculated that Anx induces different signalling axes for BMDC cy-
tokine suppresssion and T cell suppression. Particulate presentation of Anx might enhance
affinity or interaction duration at its receptor or alternatively incorporate additional re-
ceptors which counteract the effects on BMDC cytokines while the effects mediating T cell
suppression are maintained.
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5.3 Anx affecting DC-T cell interaction
Inhibition of the T cell responses was a shared result mediated by BMDC treated with
soluble and particulate Anx (fig. 4, fig. 5) but the underlying mechanism still need to be
elucidated.
IL-10, TGF-β and IDO, which are common regulatory mediators, were not detectable
following Anx-treatment of BMDC (data not shown, fig. 9B). Moreover, washing BMDC
prior to T cell co-culture suggests a minor role of soluble mediators for the suppressive
outcome of BMDC/Tcell interaction (fig. 10). Although the production of soluble medi-
ators after the media exchange cannot be excluded, this data implies that Anx exerts its
function mainly in contact-dependent manner, which is in line with reports showing that
the tolerogenic effects of apoptotic cells require cell-cell-contact 71,273.
BMDC/Tcell interactions include TCR stimulation by pMHC and co-stimulatory and
co-inhibitory signals. Figure 7 showed that antigen presentation was not affected by Anx.
The comparable phagocytosis (fig. 7A-7C) and Ova processing (fig. 7D) of control and
Anx-beads in addition to the experiments with soluble Anx, in which Ova was separately
delivered 7 h after Anx (fig. 4), indicate that T cell responses were not attenuated due
to reduced antigen availability. Whether Ova was equally presented within the MHC
could not be analysed directly. Anx did not cause changes in the overall expression of
MHC II (fig. 11E, fig. 12A). Furthermore, extracellular loading of MHC II with Ova pep-
tide after bead treatment demonstrated indirectly that Anx-mediated T cell suppression
did not rely on altered antigen presentation but is rather caused by intrinsic alterations
in BMDC (fig. 7E-7G).
As discussed in 5.1, the co-modulatory molecules CD40, CD80, CD86, PD-L1, PD-L2
and ILT3 were not targeted by Anx. ICOSL, which has a dual role as co-stimulatory
and co-inhibitory molecule 34,35, was not significantly affected by Anx, either. However, a
slight upregulation was observed in figure 12B. This trend probably plays no major role
in the initiation of Anx-mediated T cell tolerance but it might contribute to secondary
BMDC/Tcell interactions e.g. following a shift in the receptors involved in co-stimulation
of T cells. In this context, it would be interesting to analyse the expression of ICOS and
CD28 on the T cells.
Another modulator of the BMDC/Tcell interaction might be H2O2. When DC and T cell
form an immunological synapse, the cells are in close contact so that DC-derived H2O2
could diffuse into the T cell 257. Cemerski et al. demonstrated that neutrophil-derived
ROS or treatment with H2O2 inhibited DNA synthesis in T cells resulting in reduced
proliferation, NFAT activation and IL-2 production. ROS is however also described to
positively influence T cell activation 274,275 but it should be noted that these reports include
effects of T cell-intrinsic ROS. The level and location or source of ROS can impact the type
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of modulation. Whether the Anx-dependent ROS production illustrated in figure 13 acts
in an autocrine or paracrine way or both needs to be further investigated e.g. by using
ROS scavengers or NOX2 inhibitors. Moreover, the ROS levels during BMDC/Tcell co-
culture must be analysed since the present study only demonstrated ROS generation by
BMDC shortly after Anx encounter.
In summary, Anx most likely exerts its regulatory function in a contact-dependent manner
but the molecules and mechanisms involved could not be identified in this study.
5.4 Anx attenuates Ova-specific T cell responses
Anx-treated BMDC dampen T cell proliferation and cytokine production (fig. 4, fig. 5,
fig. 14) indicating a shift in the T cell phenotype that might lead to T cell tolerance.
The deletion of autoreactive T cells is one type of T cell tolerance resulting from repeated
antigen stimulation. 83 Since the T cell viability in the presented experiments remained at
around 80% and was not specifically altered by Anx-beads (fig. 6B), it is unlikely that
Anx promotes CD4+ Tcell deletion in vitro.
The two other types of T cell tolerance, Treg and anergy, are both associated with in-
creased expression of co-inhibitory receptors. 109,221 However, no Anx-mediated changes
were observed in the surface expression of CTLA-4, PD1 and Lag-3 (fig. 15B-15D).
CTLA-4 is internalised and recycled upon ligation leading to a rapid turnover and to
an intracellular location of a high proportion of the protein 16,221. Thus, the involvement
of CTLA-4 in Anx-mediated effector mechanism cannot be definitely excluded until intra-
cellular and/or mRNA levels of CTLA-4 are investigated. Moreover, the ratio of CTLA-4
and CD28 expression should be analysed. CTLA-4 binds the same ligands (CD80, CD86)
as CD28 but with a higher affinity 16,17. A downregulation of CD28 in combination with
high levels of CD80/CD86 could enhance CTLA-4 activity irrespective of unaltered ex-
pression of CTLA-4 itself. A potential role of CTLA-4 could be further investigated using
CTLA-4 blocking antibodies.
Tim-3 was described as negative regulator of TH1 responses
22. Figure 15E shows a signi-
ficant but small increase in Tim-3 expression caused by Anx. Tim-3 was only expressed
in a subpopulation of the cells (data not shown) and thus it seems unlikely that Tim-3
has a major role in the Anx-mediated T cell regulation. Nonetheless, the effect of Tim-3
blockade should be examined. Furthermore, Tim-3 should be assessed in the context of
PD-1 since it is reported to act cooperatively with PD-1 22 and the effects on either of the
co-receptors may be more pronounced in a double positive population. If Anx promotes
the generation of a Tim-3+, PD1+ Tcell population it would be interesting to separately
investigate this population in more detail. Tim-3 could point to a regulatory T cell sub-
set as it was observed to be upregulated in some FoxP3+ Treg 22. However, figure 15A
illustrates that Anx-bead treated BMDC did not induce FoxP3 expression in T cells.
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Anx did generally not seem to mediate the conversion into Treg cells in vitro. The different
Treg subsets are characterised by FoxP3 expression, IL-10 secretion or TGF-β secretion.
None of these properties were observed in T cells following co-culture with Anx-bead
treated BMDC (fig. 14B-14C, fig. 15A).
While Treg cells are often characterised by functional mediators, anergy is mainly de-
scribed by the lack of effector function 87,221. The reduced proliferation and cytokine
production, especially of IL-2, mediated by Anx (fig. 4, fig. 5, fig. 14) represents this basic
definition leading to the hypothesis that Anx induces anergy. Anergic T cells develop upon
suboptimal T cell stimulation like TCR signalling in the absence of co-stimulation 91,221,276.
The lack of CD28 signalling can result in an alternative gene programme including tran-
scription of Cblb, GRAIL and Egr2 87,94,98,101,102. Egr2 is an early response gene that
further promotes transcription of the mentioned E3 ubiquitin ligases and its mRNA ex-
pression was shown to be increased up to 100-fold in the first 3 h after TCR stimulation 95.
This anergy-related gene signature was not observed after 4 h (fig. 16C-16E) or 24 h (data
not shown) of T cell co-culture with Anx-treated BMDC. A modulation at the protein
level or of the activity of Cblb and GRAIL was not analysed and cannot be excluded.
A primary outcome of the signalling via NFAT in the absence of AP-1 is diminished
IL-2 transcription which is also a hallmark of anergy 87. In spite of the presence of co-
stimulation (fig. 11, fig. 12) and the unaltered transcription levels of anergy-related genes
(fig. 16C-16E), IL-2 transcription in T cells was markedly reduced by Anx-beads and sol-
uble Anx (fig. 16B, fig. S6A). Activation and DNA-binding of both NFAT and AP-1 is
required for IL-2 transcription and it should be further examined whether AP-1 translo-
cation is impaired in Anx-dependent manner. In addition to NFAT and AP-1, a variety
of other molecules and transcription factors are involved in the regulation of IL-2 trans-
cription. For instance, RhoA, Ikaros and SATB1 counteract histone acetylation at the
IL-2 promoter restricting its accessibility and thus inhibit IL-2 transcription. 277–279 mi-
croRNAs like miR146a can also interfere with IL-2 transcription. miR146a impairs AP-1
production 280 and is further described to downregulate Stat1 and to limit TRAF6 and
IRAK signalling 281,282. These examples illustrate that the identification of IL-2 transcrip-
tion as an Anx-mediated effect unveils a plethora of potential targets.
In summary, Anx mediates neither T cell deletion nor Treg induction in vitro while it
does mediate an anergy-like phenotype. However, not all properties associated with an-
ergic T cells were observed in the treated T cells. A microarray analysis could help to
further analyse the T cell phenotype and to identify molecules and pathways involved in
the attenuation of the T cell response.
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5.5 Anx-beads in vivo
The immunospressive capacity of Anx-beads illustrated in vitro needs to be confirmed in
vivo to asses their potential value for future therapies.
In contrast to the in vitro data, Anx-beads did neither reduce proliferation nor cytokine
production of OT-II T cells in vivo (fig. 19). The cytokine response was however difficult
to evaluate. The treatment with control-beads did not result in sufficient IFN-γ secre-
tion, even when administered in the presence of co-stimulatory agents (fig. 17E, fig. 18D,
fig. 19E, 19J) and thus it was not feasible to detect a potential inhibition of IFN-γ. In
spite of IL-2 levels above the baseline (set as the level in mock treated mice) (fig. 18C,
fig. 19D, 19I), no clear conclusion could be drawn comparing the levels of IL-2 induced
by control- or Anx-beads. Only two experiments with 3 mice per group each were per-
formed with Anx-beads. Besides high variation especially in the experiment with polyI:C
(fig. 19I), the two experiments showed contradicting trends. Figure 19D shows slightly
decreased to similar levels of IL-2 in Anx-bead-treated mice compared to control-bead-
treated mice, whereas figure 19I shows rather increased IL-2 production from mice treated
with Anx-beads in the presence of polyI:C.
Proliferation alone is not a sufficient readout to determine the type of T cell response
induced by the beads as initial proliferation is observed for inflammatory and tolerogenic
T cell responses 88,283–285. The absolute number of OT-II T cells detected in the spleen
6 days after treatment was lower in Anx-bead-treated mice compared to control-bead-
treated mice (fig. 19B, 19G,). This might indicate T cell deletion but larger groups of
mice are necessary to show whether this effect is significant. In addition, evaluation of
later time points is necessary to validate T cell deletion. The latter is especially inter-
esting since anergy can develop in parallel to deletion. While most of the T cells die
after proliferation, the small population that survives was found to be anergic 88,283. The
experimental setup was modified to investigate late T cell phenotypes. Splenocytes were
harvested 9 days after treatment or 3 days after a challenge with OVA/CpG given 10 days
after the primary treatment (data not shown). However, only inadequate numbers of
transferred OT-II T cells were detected in these experiments, even in mice treated with
Ova/αCD40. These technical issues need to be solved to examine the longterm Tcell
response. Furthermore, the effects of beads on an established immune response should be
investigated. Figure 14D-14E indicates that Anx-beads could diminish cytokine secretion
from preactivated OT-II T cells, hence in vivo experiments in mice primed with Ova prior
to bead treatment should be performed.
Anx-mediated T cell suppression was not observed in the presented in vivo experiments
which may be due to the above discussed limitation in the experimental setup. Another
possible reason for the diverging results in vitro and in vivo is the fact that the beads
encounter different cell subsets. The function of the beads described in vitro was initiated
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via BMDC, which are an artificial and heterogeneous cell population that has no exact
counterpart in vivo 286–288. Following i.v. injection, the beads are presumably taken up by
splenic CD8α+ DC and/or marginal zone macrophages 120,154. Whether the beads affect
these cell subsets similarly to BMDC is yet to be investigated.
A final conclusion about the tolerogenic potential of Anx-beads in vivo can not be drawn
and further experiments including the use of adoptively transferred OT-II T cells and the
stimulation of endogenous T cell populations are needed. And eventually, the beads must
be analysed in pathologically relevant mouse models.
5.6 Anx-coated PLGA nanoparticles
PLGA was chosen as FDA-approved basis for the generation of an Anx-containing antigen
delivery system to facilitate translation into a clinical setting. Anx-NP were encapsulated
with Ova while Anx was covalently attached to the NP-surface. Although the ratio of
Anx:Ova was similar on beads and NP, Anx-NP had no suppressive activity in vitro
(fig. 20, fig. 21).
This lack of function may be caused by differential protein loading. Since NP-treated
BMDC provoke OT-II T cell responses (fig. 21B-21G), it can be inferred that Ova en-
capsulation did not adversely affect protein integrity or availability of Ova. The coating
of Anx was analysed and confirmed by Nanovex Biotechnologies. However, the conform-
ation of Anx at the particle-surface is unknown. The covalent attachment might affect
protein folding and could thus mask or disrupt the signalling-relevant domains of Anx.
Whether the covalent binding of Anx interferes with its function is however difficult to
test. On the one side, the molecular interaction partner and hence the corresponding
binding site of Anx was not yet identified. Additionally, the spatial organisation of Anx
on the particle-surface may effect efficient receptor-interaction 179. On the other side, the
anti-inflammatory capacity of Anx was mainly analysed with indirect assays which can
be affected by many variables. The only direct readout identified so far is ROS produc-
tion, hence ability of Anx-NP to induce ROS may reveal the functional status of the
NP-coupled Anx.
Despite appropriate protein coating, the function of NP is highly influenced by gen-
eral properties like size and charge which could antagonise immunosuppressive effects of
Anx. Inflammatory as well as anti-inflammatory effects are reported for PLGA-NP en-
capsulated with antigen 154,160. The NP used in the present study showed no intrinsic
pro-inflammatory activity, since IL-6 secretion and the expression of maturation markers
were not increased in BMDC by the control-NP treatment (fig. 20A-20D). Intrinsic anti-
inflammatory properties were not observed, either (fig. 20F-20L) and thus the NP seem
to be an inert verhicle.
Anx-NP failed to dampen T cell responses (fig. 21) but many variables could be adjusted
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to improve the function of Anx-NP. Although even experts in the field admitted that it
can be challenging to transfer a concept from one particle type to another and to reach
optimal properties with PLGA-NP 154, PLGA-NP are a promising carrier system that is
now clinically tested 182. A number of studies reported a tolerogenic effect of PLGA-NP
with negative ζ-potential 161–164 and thus a first attempt to improve Anx-NP could be the
generation of negatively-charged Anx-NP.
5.7 Conclusion
This study describes a particle-based delivery system with the capacity to promote antigen-
specific tolerance.
In vitro, polystyrene beads coated with Anx and the model antigen Ova induced an
anergy-like phenotype represented by reduced proliferation, IFN-γ and IL-2 secretion.
The most pronounced effects were observed on IL-2 production and could be attributed
to attenuated IL-2 transcription. Impaired IL-2 transcription is a hallmark of anergy
resulting from TCR stimulation in the absence of co-stimulation which in turn leads to
an altered gene transcription programme. The anergy-associated genes analysed in this
study were not regulated by Anx-beads and additional studies are needed to identify the
mechanisms leading to reduced IL-2 transcription and to further characterise the induced
T cell phenotype.
The outlined T cell suppression is a DC-mediated effect. The treatment of BMDC with
Anx-beads did not result in a tolerogenic phenotype typically described by the secretion
of anti-inflammatory cytokines and reduced expression of co-stimulatory markers and the
distinct mechanisms used by the treated DC to regulate the T cell response remain elusive.
However, this study revealed that the suppression of T cell responses is a Anx-mediated
function which is independent of the inhibition of pro-inflammatory cytokines that was
previously described and confirmed in the present study for soluble Anx. Furthermore,
this study is the first to show that Anx induces ROS production in BMDC. Whether
and how this ROS signal influences DC and the DC/T cell interaction needs to be further
investigated.
The immunosuppressive function of the Anx-beads could not be validated in vivo, yet, and
additional experiments are needed to delineate the effects of these beads under physiolo-
gical conditions as well as in pathologically relevant models.
In addition to the polystyrene-beads, an alternative vehicle that is more suitable for
clinical use was generated with the FDA-approved polymer PLGA. However, the Anx-
NP examined in this study showed no immunosuppressive function. The properties of
the PLGA-NP need to be improved to reproduce the effects observed with polystyrene-
beads since the translation to a clinically relevant material is indispensable to develop
an Anx-dependent tolerogenic antigen delivery system as a new therapeutic approach for
67
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autoimmune disease.
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Appendix
I Supplementary results
Bead optimisation
The bead preparation had to be optimised and controlled before the functional experi-
ments described in the results section could be performed. The final bead preparation
protocol is visualised in figure S1. Beads are first coated with Ova to ensure equal Ova-
Figure S1: Bead preparation protocol. Beads were added to a Ova-solution in DPBS and
rotated overnight (o/N), allowing passive adsorbtion of Ova to the bead surface. Following overnight
incubation, beads were washed to remove unbound protein. Ova-coated beads were split and one
part was coated additionally with Anx by o/N rotation. Beads were again washed and then blocked
with DPBS containing 1% mouse serum.
loading on different types of beads and in the end blocked with mouse serum (ms). It is
noteworthy that the beads were initially produced without blocking and results generated
with both blocked and unblocked beads are incorporated in the presented results. For
example, figure 5 shows data from the initial unblocked bead preparations.
The first attempts to produce beads harbouring Ova and Anx utilised αFlag-antibodies to
control Anx orientation on the beads. However, the presence of the antibody on the bead
surface markedly reduced the IL-6 secretion of BMDC which did however not impede the
subsequent T cell proliferation (fig. S2A, S2B). Beyond the altered IL-6 suppression, the
presence of αFlag abrogated the Anx-mediated inhibition of T cell responses as observed
when comparing beads with direct Anx-coupling (OB, OAB) and beads with αFlag as
vehicle for Anx-coupling (OFB, OFAB) (fig. S2C-S2F). As a consequence of these res-
ults showing unspecific modulation on BMDC by α-Flag, Anx was directly coated to the
beads. Furthermore, the functional coating of Anx was efficient without the antibody as
vehicle.
The blocking step was established after functional experiments were successfully per-
formed. However, alteration became necessary following an inexplicable loss of OAB
activity. In this context, different buffers (PBS, DPBS, DPBS-Ca2+) were tested in com-
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(A) (B) (C)
(D) (E) (F)
Figure S2: αFlag is no suitable vehicle for Anx-coating to beads. BMDC were pre-
incubated with beads and stimulated with CpG. CFSE-labelled OT-II T cells were co-cultured with
the treated BMDC. Proliferation was evaluated after 5 days of co-culture (B+F). Supernatants for
cytokine analysis were collected before T cells were added (A+C) and on day 2 (D) and day 5 of
co-culture (E).
bination with different blocking agents (FCS, BSA, ms) (fig. S3). Western blot analysis
demonstrated stable and high affinity attachment of Anx to the beads in all tested con-
ditions (data not shown) whereas the western blot analysis of Ova attachment were in-
conclusive. Ova was coupled to the beads as illustrated in figure S3A by comparing the
protein in solution before the beads were added (SN input) and the protein that remained
in solution after coating (SN unbound). Although the analysis of the supernatant implies
that up to 7 ng Ova were bound to 106 beads, examination of the beads by western blot
did not represent increasing concentrations of Ova. Desorption of Ova from the beads
could explain this phenomenon. To test this hypothesis, the protein content in the bead
solution after pelleting the beads was analysed. No Ova was detectable in supernatants
taken from beads stored for several weeks (data not shown). Furthermore, neither soni-
fication nor incubation in media at 37 ◦C resulted in detectable amounts of Ova in bead
supernatants (fig. S3B, S3C) disproving the hypothesis of Ova desorbtion.
Interestingly, the beads recovered from the medium seemed to have a higher Ova content
than beads from the bead stock which was stored at 4 ◦C in the meantime. Beads blocked
with FCS were an exception, since comparable amounts of Ova were detected before and
after medium incubation(fig. S3C). This indicates that blocking with medium or FCS
may modulates Ova attachment and that western blot results were not representative for
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(A)
(B)
(C)
(D)
Figure S3: Attachment of Ova to beads is very stable (A-C) Bead supernatants (SN) or
beads were incubated in SDS buffer at 95 ◦C for 15min, loaded to SDS-PAGE to detect Ova via
western blot. (A) illustrates the coupling of different amounts of Ova to beads. SN input are samples
of the protein solution before the beads were added. SN unbound shows protein that remained in
solution after incubation with the beads. (B) SN from beads generated in different buffers were
analysed before and after brief sonificatio. (C) Beads generated in different buffers were incubated
in medium at 37 ◦C. Beads and medium were then separated by centrifugation and protein content
was compared with bead stocks stored at 4 ◦C. (D) Ova-FITC content on the bead surface was
measured by FC before and after beads were incubated in SDS buffer at 95 ◦C for 15min.
Ova coating of unblocked beads. A FITC-labelled variant of Ova was then utilised to
examine the Ova content on the beads directly via FC. First, it was investigated whether
the sample preparation for western blot analysis was efficient. Hence, beads were analysed
by FC before (fig. S3D, upper panel) and after (fig. S3D, lower panel) they were cooked
in SDS-buffer at 95 ◦C for 15min. The harsh treatment was not sufficient to elute Ova
completely from the beads. Moreover, considerably more residual Ova was detected on
beads that were not blocked with serum or supplemented with Anx. Thus, it can be hy-
pothesised that in Ova binds tightly to the beads and in this context may even change its
conformation or unfold when there is no other protein that restricts the binding space on
the bead surface. This type of binding to the beads might also influence the availability
of the antigen in the cells. Blocking with mouse serum was introduced into the standard
bead production to avoid such effects.
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(A) (B)
Figure S4: Different bead charges are comparably
coated. Bead coating was analysed by FC. Proteins were de-
tected directly (Ova-FITC) or by staining with a fluorescent
antibody (αAnx-APC). Different bar colours indicate different
bead charges.
Coating was regu-
larly controlled by
FC exploiting the
direct label of Ova
and staining Anx
with an APC-labelled
antibody. Com-
parison of different
bead charges as ex-
emplified in figure
S4 demonstrated that
the refined bead pro-
duction protocol res-
ults in reproducible bead coating in different bead charges.
Bead effects on BMDC cytokines
The functional analysis of the beads was preceded by titration experiments to assess the
optimal bead concentration. The results from the titrations on T cell level are shown in fig-
(A) (B)
(C) (D)
Figure S5: BMDC cytokine production following incubation with Anx-beads. (A+B)
BMDC were pre-incubated with indicated concentrations of Ova-beads (OB) and stimulated with
CpG. Cytokine secretion was analysed 2 days after stimulation. (C+D) BMDC were pre-incubated
with soluble Ova [10µg/ml] or beads [14 106/ml] and optionally stimulated with CpG as indicated.
Cytokine secretion was analysed 2 days after stimulation.
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ure 5B-5D while figure S5A-S5B exemplifies the effects of the control-beads on BMDC cy-
tokine production. IL-6 and IL-12 secretion is decreased in bead-concentration-dependent
manner.
Figure S5C-S5D illustrates BMDC cytokine secretion from an T cell suppression as-
say. This raw data further demonstrates that neither control nor Anx-beads have pro-
inflammatory effects on BMDC at the cytokine level.
Effects of soluble Anx on anergy-related genes
Soluble Anx mediated attenuation of T cell proliferation, IL-2 and IFN-γ secretion, indic-
ating an anergic phenotype. Similar to the results obtained with the Anx-beads, T cell
interaction with BMDC treated with soluble Anx impaired IL-2 transcription (fig. S6A)
whereas other anergy-related genes were not affected (fig. S6B-S6D).
(A) (B) (C) (D)
Figure S6: IL-2 is the only anergy-related genes are affected by soluble Anx BMDC were
pre-incubated for 7 h with Anx [1000 nM] before Ova [10µg/ml] and, 1 h later, CpG were added.
CFSE-labelled OT-II T cells were co-cultured with treated BMDC for 4 h before they were harvested
and analysed via qRT-PCR using HPRT as reference gene. (A) IL-2 expression is shown relative to
the expression in the Ova-treated condition. (B-D) Expression of the indicated genes is illustrated
relative to the expression of T cells co-cultured with non-pre-treated but CpG-stimulated BMDC.
Dots indicate independent experiments.
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II List of Abbreviations
aJ Apoptotic JE6.1
Anx Annexin/annexin core domain
AP-1 Activator protein 1
APC Antigen presenting cell
APC (conjugate) Allophycocyanin
BMDC Bone marrow derived dendritic cells
BSA Bovine Serum Albumin
C57BL/6 C57 Black 6 mouse
CD Cluster of differentiation
conc Concentration
CTL Cytotoxic T lymphocytes
CTLA-4 Cytotoxic T-lymphocyte-associated Protein 4
DC Dendritic cell
DCFDA 2’,7’-dichlorofluorescein-diacetate
dNTP Desoxynucleosidtriphosphate
EAE Experimental Autoimmune Encephalomyelitis
ECDI 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
ECL Enhanced chemiluminescence
Egr2 Early growth response protein 2
ELISA Enzyme Linked Immunosorbent Assay
ELISpot Enzyme Linked Immunospot Assay
EMA European Medicines Agency
ER Endoplasmatic reticulum
FACS Fluorescent Associated Cell Sorting
FC Flow Cytometry
FCS Fetal Calf Serum
FDA Food and drug administration
FITC Fluorescein-isothiocyanate
FoxP3 Forkhead box P3
FPR Formyl Peptide Receptor
GRAIL Gene related to anergy in lymphocytes
HA Influenza Hemagglutinin
HRP Horse Radish Peroxidase
ICOS Inducible T cell co-stimulator
ICOSL ICOS-ligand
IDO Indoleamine-pyrrole 2,3-dioxygenase
IFN Interferon
92
IgG Immunoglobulin G
IL Interleukin
ILT Immunoglobulin-like transcript
ITAM Immunoreceptor tyrosine-based activation motif
ISQ Ovalbumin-derived MHC II peptide
i.v. Intravenous
Lag-3 Lymphocyte activation gene 3
LPS Lipopolysaccharide
OAB Ova-Anx-beads
OANP Ova-Anx-nanoparticle
OB Ova-beads
ONP Ova-nanoparticle
OPD o-phenylenediaminedihydrochloride
Ova Ovalbumin
PBMC Peripheral blood mononuclear cells
PEG Polyethylene Glycol
PI3K Phosphatidylinositide 3-kinases
PKC Protein kinase C
PLC Phospholipase C,
PLGA Poly(lactic-co-glycolic acid)
Mφ Macrophage
MHC Major histocompability complex
MS Multiple Sclerosis
ms Mouse serum
mTEC Medullary thymic epithelial cells
NFAT Nuclear factor of activated T-cells
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells
NOX2 NADPH oxidase 2
NP Nanoparticle
PAGE Polyacrylamide Gel Electrophoresis
PAMP Pathogen-associated molecular pattern
PBS Phosphate Buffered Saline
PBS-T Phosphate Buffered Saline - Tween 20
PCR Polymerase Chain Reaction
PD-1 Programmed cell death protein 1
PD-L1/2 Programmed cell death 1 ligand 1/2
PE Phycoerythrin
PEI Polyethylenimin
PenStrep Penicillin Streptomycin
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PKC Protein kinase C
PLGA Poly(D,L-lactide-co-glycolide)
PMA Phorbol myristate acetate
PmxB PolymyxinB
PS Phosphatidyl serine
PRR Pattern recognition receptor
RES Reticulo-endothelial System
pMHC peptide-MHC complex
ROS Reactive Oxygen Species
PRR Pattern recognition receptor
RPMI Roswell Park Memorial Institute
RT Room Temperature
SIINF Ovalbumin-derived MHC I peptide
SIY Control Peptide
SN Supernatant
SOCS Suppressor Of Cytokine Signalling
T1D Type 1 Diabetes
TCR T cell receptor
TBS Tris Buffered Saline
TBS-T Tris Buffered Saline - Tween 20
TGF-β Transforming growth factor β
TH cells T helper cells
TLR Toll-like receptor
Tim-3 T cell immunoglobulin 3
TNF Tumor necrosis factor
tolDC Tolerogenic DC
Tr1 cell Type 1 regulatory cell
Treg Regulatory T cell
Trolox 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carbonsa¨ure
wt Wild type
94
III List of Figures
1 T cell co-stimulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
2 T cell activation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
3 Suppression BMDC cytokine production following incubation with apop-
totic cells or Anx. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
4 Reduction of Ova-specific T cell stimulation following pre-incubation with
soluble Anx. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
5 Attenuation of Ova-specific T cell stimulation by Ova-Anx-beads. . . . . . 37
6 Viability of BMDC and T cells is not impaired by beads. . . . . . . . . . . 38
7 Bead uptake, Ova processing and Ova presentation are not significantly
altered by Anx.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
8 Diminished T cell responses are independent of BMDC cytokine suppression. 41
9 Expression of IL27, IDO, SOCS1 and SOCS3 was not modulated by Anx. . 42
10 Soluble mediators have a minor role for T cell suppression by beads. . . . . 43
11 Alterations in BMDC surface marker expression by apoptotic cells and
soluble Anx.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
12 Alterations in BMDC surface marker expression by beads. . . . . . . . . . 45
13 ROS production is increased by soluble Anx and Anx-beads. . . . . . . . . 45
14 Global T cell cytokine suppression by Anx-beads. . . . . . . . . . . . . . . 46
15 Anti-inflammatory marker are scarcely influenced by Anx-beads. . . . . . . 47
16 An anergic phenotype is only partly observed in Anx-bead treated T cells. . 48
17 T cell proliferation in vivo is induced by control-beads in a concentration
dependent manner. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
18 Co-stimulation with αCD40 was not sufficient to induce antigen-specific
cytokine responses in vivo. . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
19 Anx-beads induce similar responses as control-beads in vivo. . . . . . . . . 53
20 Nanoparticle show only minor effects on BMDC phenotype. . . . . . . . . . 54
21 Attenuation of Ova-specific T cell stimulation was not reproduced by Anx-NP. 56
S1 Bead preparation protocol. . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
S2 αFlag is no suitable vehicle for Anx-coating to beads. . . . . . . . . . . . . 88
S3 Attachment of Ova to beads is very stable . . . . . . . . . . . . . . . . . . 89
S4 Different bead charges are comparably coated. . . . . . . . . . . . . . . . . 90
S5 BMDC cytokine production following incubation with Anx-beads. . . . . . 90
S6 IL-2 is the only anergy-related genes are affected by soluble Anx . . . . . . 91
95
